

1. Bendtzen K, Lindahl-Olsen A. Ampicillininduceret bakteriuri hos børn. Ugeskr Læg 1973; 135: 1327-1329.
2. Bendtzen K, Andersen V, Bendixen G. An in vitro assay of leukocyte migration inhibitory activity from human lymphocytes stimulated with concanavalin A. Acta Allergol 1975; 30: 133-149.
3. Bendtzen K, Søborg M. Sclerosing peritonitis and practolol. Lancet 1975; i:629 (letter).
4. Bendtzen K, Lyngborg K, Sandoe E, Søborg M. Skleroserende peritonitis under praktolol-(Eraldin)-behandling. Ugeskr Læg 1975; 137: 2194-2196.
5. Bendtzen K. Drug effects on human leucocyte migration and migration inhibitory activity from lymphocytes stimulated with concanavalin A. Acta Path Microbiol Scand Sect.C 1975; 83: 447-454.
6. Bendtzen K. Inhibition of human leukocyte migration inhibitory factor (LIF) by alfa-L-fucose. Acta Allergol 1975; 30: 327-338.
7. Coeugnet E, Bendtzen K, Bendixen G. Leucocyte migration inhibitory activity of concanavalin A-stimulated lymphocytes. Modification by dipyrindamole, lysine-acetylsalicylate and heparin. Acta Med Scand 1976; 199: 99-104.
8. Bendtzen K. Affinity chromatography. A new technique for partial purification of human leucocyte migration inhibitory factor. J Immunol Methods 1976; 11: 147-151.
9. Bendtzen K. Cellemedieret hypersensibilitet og lymfokiner. Ugeskr Læg 1976; 138: 2859-2863.(Review).
10. Bendixen G, Bendtzen K, Clausen JE, Kjaer M, Soeborg M. Human leucocyte migration inhibition: in vitro techniques and applications. Scand J Immunol 1976; Suppl 5: 175-184. (Review).
11. Bendtzen K. Some physicochemical properties of human leucocyte migration inhibitory factor (LIF). Evidence for the participation of a reactive serine in the LIF molecule. Acta Path. Microbiol Scand Sect.C 1976; 84: 471-476.
12. Bendtzen K. Partial purification of human leucocyte migration inhibitory factor (LIF) by immunosorption of supernatant protein contaminants detected by crossed immunoelectrophoresis. J Immunol Methods 1976; 13: 321-331.
13. Coeugnet E, Bendtzen K, Søeberg B, Bendixen G. Leucocyte migration inhibitory activity of concanavalin A-stimulated lymphocytes: in vivo and in vitro modifications by dipyrindamole and acetylsalicylic acid. Acta Med Scand 1977; 201: 197-201.
14. Bendtzen K. Human leukocyte migration inhibitory factor (LIF). I.Effect of synthetic and naturally occurring protease inhibitors. Scand J Immunol 1977; 6: 125-131.
15. Bendtzen K. Human leukocyte migration inhibitory factor (LIF). II.Partial biochemical characterization of the substrate specificities for this lymphokine. Scand J Immunol 1977; 6: 133-140.
16. Bendtzen K. The production of heterologous antibodies to the human lymphokine: leukocyte migration inhibitory factor (LIF). Cell Immunol 1977; 29: 382-393.
17. Bendtzen K, Palit J. In vitro modulation of human leucocyte migration and migration inhibitory factor (LIF) activity by cyclic 3',5'AMP and cyclic 3',5'-GMP. Acta Pathol Microbiol Scand Sect C 1977; 85: 78-80.
18. Bendtzen K, Palit J. Modulation of human leucocyte migration inhibitory factor (LIF) by cyclic 3',5'-AMP, cyclic 3',5'-GMP and agents known to influence intracellular cyclic nucleotide metabolism. Acta Pathol Microbiol Scand Sect C 1977; 85: 317-323.
19. Bendtzen K. Human leukocyte migration inhibitory factor (LIF). III.Further investigations on the serine protease nature of this lymphokine and its preference for arginine amides. Scand J Immunol 1977; 6: 1055-1062.
20. Bendtzen K, Thode J, Nistrup Madsen S. Effect of human leucocyte migration inhibitory factor (LIF) on cyclic AMP levels of peripheral blood leucocytes. Acta Pathol Microbiol Scand Sect C 1977; 85: 473-479.
21. Bendtzen K. Human leukocyte migration inhibitory factor (LIF). IV.3',5'-cGMP protects LIF against inactivation by the esterase inhibitor phenylmethylsulfonyl fluoride. Scand J Immunol 1977; 6: 1357-1361.

22. Sørensen SF, Andersen V, Bendtzen K, Fulpius BW, Krarup C, Monnier VM, Permin H, Platz P, Søbørg B, Thomsen M. Immunological studies in thymectomized and non-thymectomized patients with myasthenia gravis. *J Clin Lab Immunol* 1978; 1: 169-178.
23. Palit J, Bendtzen K, Andersen V. Production of leukocyte migration inhibitory factor (LIF) in infectious mononucleosis. Spontaneous release and lack of response to concanavalin A. *Clin Exp Immunol* 1978; 31: 66-71.
24. Bendtzen K. Human leukocyte migration inhibitory factor (LIF). V. Specific regulation of the lymphokine serine protease activity by 3',5'-cGMP and, possibly, 2',3'-cCMP. *Scand J Immunol* 1978; 8: 53-61.
25. Bendtzen K. Biological properties of lymphokines. *Allergy* 1978; 33: 105-119. (Review).
26. Bendtzen K. Determination of the human lymphokine leukocyte migration inhibitory factor (LIF) by a sensitive radioenzymatic assay. Inhibitory effect of cGMP on the esterolytic activity of highly purified LIF. *J Clin Lab Immunol* 1979; 2: 37-43.
27. Bendtzen K. Leukocytmigrationshæmmende faktor (LIF). Fra biologisk test til biokemisk karakteristisk af dette lymfokin. *Ugeskr Læg* 1979; 141: 377-380. (Review).
28. Bendtzen K. Leukocyte migration inhibitory factor. A serine esterase released by stimulated human lymphocytes. Kinetic analysis and inhibition by cyclic GMP. *Biochim Biophys Acta* 1979; 566: 183-191.
29. Bendtzen K, Klysner R. Increased polymorphonuclear leukocyte cGMP levels induced by the human lymphokine, leukocyte migration inhibitory factor (LIF). *Immunopharmacol* 1979; 1: 323-330.
30. Bendtzen K. Biochemical characterization of the human lymphokine leukocyte migration inhibitory factor (LIF): Role of cGMP as a specific inhibitor of the LIF esterase activity. *Adv Exp Med Biol* 1979; 114: 485-490.
31. Bendtzen K. Substrate specificity of the human lymphokine leukocyte migration-inhibitory factor (LIF): Radioenzymic assay and inhibition by cGMP. *Scand J Immunol* 1979; 10: 61-67.
32. Bendtzen K. Evidence for the esterase and protease nature of human leukocyte migration inhibitory factor (LIF) and its modification by cGMP. *Lymphokine Reports* 1980; 1: 41-62. (Review).
33. Rocklin RE, Bendtzen K, Greineder D. Mediators of immunity: Lymphokines and monokines. *Adv Immunol* 1980; 29: 55-136. (Review).
34. Bendtzen K. Biological properties of lymphokines with special reference to the human leukocyte migration inhibitory factor (LIF). FADL's Forlag. København, Aarhus, Odense, 1980. (Thesis/Review).
35. Bendtzen K. Molecular biology of human leukocyte migration inhibitory factor (LIF). Modulation of LIF-induced esterolysis and neutrophil migration inhibition by cGMP. Proceedings of the Second International Lymphokine Workshop. New York: Academic Press, 1980: 99-104.
36. Bendtzen K. Biological properties of lymphokines with special reference to the human leukocyte migration inhibitory factor (LIF). *Ugeskr Læg* 1980; 142: 1424-1425. (Review).
37. Bendtzen K, Rocklin RE. Use of benzoyl-L-phenylalanyl-L-valyl-L-arginine (3H) methyl ester as a sensitive and selective substrate for the human lymphokine, leukocyte migration inhibitory factor (LIF). *J Immunol* 1980; 125: 1775-1781.
38. Bendtzen K, Bendixen G. Inflammatory, non-antibody lymphocytic mediators (lymphokines). *Allergie Immunologie (DDR)* 1980; 26: 293-309. (Review).
39. Bendtzen K. Differential role of Zn²⁺ in antigen- and mitogen-induced lymphokine production. *Scand J Immunol* 1980; 12: 489-492.
40. Rocklin RE, Bendtzen K. Lymphokines that affect the migration of polymorphonuclear leukocytes. In Hadden JW, Stewart WE, eds. *The Lymphokines*. New Jersey: The Humana Press, 1981: 33-53. (Review).
41. Bendtzen K, Mahoney R, Rocklin RE. Production of human leukocyte migration inhibitory factor (LIF) by lymphocytes stimulated with phytohemagglutinin. I. Effect of various metabolic inhibitors. *Clin Immunol Immunopathol* 1981; 18: 212-220.

42. Bendtzen K, Mahoney R, Rocklin RE. Production of human leukocyte migration inhibitory factor (LIF) by lymphocytes stimulated with phytohemagglutinin. II. Effects of cyclic nucleotides. *Clin Immunol Immunopathol* 1981; 18: 221-229.
43. Bendtzen K. Induction of antigen-specific immunological unresponsiveness by inhibitors of human lymphocyte-activating factor. *Scand J Immunol* 1981; 14: 427-432.
44. Dinarello CA, Bendtzen K, Wolff SM. Studies on the active site of human leukocytic pyrogen. *Inflammation* 1982; 6: 63-78.
45. Bendtzen K, Mayland L. Role of Zn²⁺ and other divalent metal ions in human lymphokine production in vitro. *Scand J Immunol* 1982; 15: 81-86.
46. Rasmussen N, Bendtzen K, Thomsen J, Tos M. Patient-specific cell-mediated immunity against human acoustic neuroma extract. *Acta Otolaryngol* 1982; 94: 261-265.
47. Petersen J, Andersen V, Bendixen G, Bendtzen K, Kristensen JH, Hansen TI, Wiik A. Functional characteristics of synovial fluid and blood mononuclear cells in rheumatoid arthritis and traumatic synovitis. *Scand J Rheumatol* 1982; 11: 75-80.
48. Bendtzen K. Induction of antigen-specific lymphocyte unresponsiveness in vitro: Possible role of divalent cations and defective function of human T-cell-activating factor (TAF). *Cell Immunol* 1982; 66: 152-163.
49. Petersen J, Bendtzen K. Involvement of monokines in antigen- and lectin-induced human lymphokine production. *Acta Path Microbiol Immunol Scand Sect C* 1982; 90: 229-235.
50. Bendtzen K, Petersen J. Effects of cyclosporin A (CyA) and methylprednisolone (MP) on the immune response. I. T cell-activating factor (IL-1) abrogates CyA- but not MP-induced suppression of antigen-induced lymphokine production. *Immunol Lett* 1982; 5: 79-83.
51. Bendtzen K, Petersen J. Effect of cyclosporin A (CyA) on the immune response. CyA competitively inhibits the function of monocyte/macrophage-derived T lymphocyte-activating factor(s). *Immunol Lett* 1982; 5: 331-336.
52. Bendtzen K, Enk C. Chelating property of D-penicillamine as a mechanism of immunosuppression in vitro. *IRCS Medical Science* 1982; 10: 815-816.
53. Clemmensen OJ, Bendtzen K, Andersen V, Wulff HC, Niebuhr E, Thomsen K, Bendixen G. Lymphocyte function and chromosome aberrations in patients with early mycosis fungoides and parapsoriasis en plaque. *J Invest Dermatol* 1983; 81: 308-313.
54. Bendtzen K, Petersen J, Sjøberg B. Effects of cyclosporin A (CyA) and methylprednisolone (MP) on the immune response. II. Further studies of the monocyte - T cell interactions leading to lymphokine production. *Acta Path Microbiol Immunol Scand Sect C* 1983; 91: 159-168.
55. Rasmussen N, Bendtzen K, Thomsen J, Tos M. Specific cellular immunity in acoustic neuroma patients. *Otolaryngol Head Neck Surg* 1983; 91: 532-536.
56. Bendtzen K. Biological properties of interleukins. *Allergy* 1983; 38: 219-226. (Review).
57. Bendtzen K. Cyclosporin A. Et anderledes immunosuppressivum. *Ugeskr Læg* 1983; 145: 2745-2748. (Review).
58. Bendtzen K. Regulation of the immune response. *Allergy* 1983; 38: 217. (Editorial/Review).
59. Petersen J, Bendtzen K. Cyclosporin A and methylprednisolone suppress antigen-induced lymphokine production at distinct sites of the macrophage - T cell cooperation processes. In: Hadden JW, Chedid L, Dukor P, Spreafico F, Willoughby D, eds. *Advances in Immunopharmacology 2*. Oxford: Pergamon Press, 1983: 854 and 859.
60. Petersen J, Bendtzen K. Immunosuppressive actions of gold salts. *Scand J Rheumatol* 1983; Suppl.51: 28-35. (Review).
61. Bendtzen K. Pathophysiological assessment - macrophages. In Lovgren O, Olhagen B, eds. *Gold in Rheumatoid Arthritis. The Past, Present and Future*. Smith, Kline & French. Stockholm 1983. (Review).
62. Bendtzen K. What is relevant to assess in clinical trials in R.A.? *Scand J Rheumatol* 1983; Suppl.51: 70-72.

63. Petersen J, Bendtzen K. Immunosuppressive actions of gold salts. In Lovgren O, Olhagen B, eds. Gold in Rheumatoid Arthritis. The Past, Present and Future. Smith, Kline & French. Stockholm 1983.(Review).
64. Bendtzen K, Petersen J. Role of monocytes/macrophages and interleukin 1 in antigen-induced human lymphokine production. *Cell Immunol* 1984; 83: 101-106.
65. Bendtzen K, Bæk L, Berild D, Hasselbalch H, Dinarello CA, Wolff SM. Demonstration of circulating leukocytic pyrogen/interleukin-1 during fever. *N Engl J Med* 1984; 310: 596 (letter).
66. Bendtzen K, Thomsen M. The T cell suppressive function of cyclosporin A is counteracted by Insulin. *IRCS Med Sci* 1984; 12: 280-281.
67. Bendtzen K, Tvede N, Andersen V, Bendixen G. Cyclosporin for polymyositis. *Lancet* 1984; i: 792-793 (letter).
68. Bendtzen K, Dinarello CA. Mechanism of action of cyclosporin A. Effect on T-cell-binding of interleukin 1 and antagonizing effect of insulin. *Scand J Immunol* 1984; 20: 43-51.
69. Svenson M, Bisgaard H, Bendtzen K. Effects of leukotrienes on neutrophil migration and on production and action of lymphokines. *Allergy* 1984; 39: 481-484.
70. Remvig L, Enk C, Bæk L, Bendtzen K. Influence of endotoxin on production of leucocyte migration inhibition factor. Part I. *J Immunol Meth* 1984; 72: 189-196.
71. Enk C, Remvig L, Bendtzen K. A standardized human T-lymphocyte proliferation assay for detecting soluble accessory factors from monocytes. I. Monocyte and monokine requirements. *Acta Path Microbiol Immunol Scand Sect C* 1984; 92: 93-100.
72. Bendtzen K, Tvede N, Svenson M. Cyclosporin (cyclosporin A): molecular biology and clinical use. *IRCS J Med Sci* 1984; 12: 874-876.(Review).
73. Bendtzen K. Cyclosporin (cyclosporin A). Prototype of a new generation of immunosuppressive drugs. *Allergy* 1984; 39: 565-571.(Review).
74. Rasmussen N, Bendtzen K, Thomsen J, Tos M. Antigenicity and protein content of perilymph in acoustic neuroma patients. *Acta Otolaryngol (Stockh)* 1984; 97: 502-508.
75. Szigeti R, Masucci G, Ehlin-Henriksson B, Bendtzen K, Henle G, Henle W, Klein G, Klein E. EBNA-specific LIF production of human lymphocyte subsets. *Cell Immunol* 1984; 83: 136-141.
76. Masucci G, Szigeti R, Stevens D, Masucci MG, Klein E, Petersen J, Bendtzen K, Klein G. Production of leukocyte migration inhibitory factor (LIF) in human lymphocyte subsets exposed to polyclonal activators. *Cell Immunol* 1984; 85: 511-518.
77. Brandt K, Pindborg JJ, Bendtzen K. Gingivale hyperplasier ved behandling med ciklosporin (cyclosporin A). *Tandlægebladet* 1984; 88: 677-680.
78. Berild D, Bendtzen K, Badsberg E. Diagnosis of Hodgkin's disease hampered by an Epstein-Barr virus infection treated with acyclovir. *Scand J Haematol* 1984; 33: 448-452.
79. Oxholm P, Winther K, Bendtzen K, Bendixen G. Lack of evidence for human lymphokines with thrombocyte aggregating activity. *Allergy* 1984; 39: 618-621.
80. Bjerrum OW, Gjedde S, Bendtzen K, Enk C, Pedersen BK, Munch Petersen B, Platz P, Wulf HC. An unusual case of multiple malignancy in an adult. *Tumori* 1984; 70: 575-577.
81. Mortensen SA, Baandrup U, Buch J, Bendtzen K, Hvid-Jacobsen K. Immunosuppressive therapy of biopsy proven myocarditis: Experiences with corticosteroids and cyclosporin. *Int J Immunotherapy* 1985; 1: 35-45.
82. Bendtzen K. Interleukins. *Comp Immunol Microbiol Infect Dis* 1985; 8: 225-234. (Review).
83. Mandrup-Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, Nerup J. Cytokines cause functional and structural damage to isolated islets of Langerhans. *Allergy* 1985; 40: 424-429.
84. Bendtzen K, Petersen J, Halkjær-Kristensen J, Ingemann-Hansen T. Interleukin-1-like activities in synovial fluids of patients with rheumatoid arthritis and traumatic synovitis. *Rheumatol Int* 1985; 5: 79-82.

85. Bendtzen K. Lymphokines in inflammation. In P.Venge & A. Lindbom (eds.). *Inflammation. Basic Mechanisms, Tissue Injuring Principles and Clinical Models*. Almqvist & Wiksell International, Stockholm, 1985: 187-217.(Review).
86. Pedersen C, Permin H, Skov PS, Norn S, Svenson M, Mosbech H, Bendtzen K. Inhibitory effect of cyclosporin A on histamine release from human leukocytes and rat mast cells. *Allergy* 1985; 40: 103-107.
87. Svenson M, Bendtzen K. Effects of cyclic GMP-agonists on ciclosporin-induced suppression of human lymphokine production. *Allergy* 1985; 40: 529-534.
88. Bendtzen K, Madsen S. International workshop om ciclosporin ved autoimmunsygdomme. *Ugeskr Læg* 1985; 147: 2470-2471.(Meeting comm.).
89. Bendtzen K, Tvede N, Andersen V, Mortensen SA. Ciclosporin (CyA) in the management of polymyositis/idiopathic cardiomyopathy. In: 'Ciclosporin in Autoimmune Diseases.' (ed. Schindler R.). Springer-Verlag, Berlin, 1985; 110-113.(Review)
90. Bendtzen K, Nissen C, Tvede N, Andersen V. Ciclosporin treatment of autoimmune inflammatory disorders of the eye. In: 'Ciclosporin in Autoimmune Diseases.' (ed. Schindler R.). Springer-Verlag, Berlin, 1985; 143-146.(Review)
91. Nissen C, Bendtzen K, Tvede N, Andersen V. The treatment of presumed non-infective uveitis with ciclosporin A. *Acta Ophthalmol* 1985; 63,Suppl. 173: 72-73.
92. Nerup J, Bendtzen K, Mandrup-Poulsen T. A role for cyclosporin A in the treatment of insulin-dependent diabetes mellitus? *Diab Med* 1985; 2: 441-446.
93. Mandrup-Poulsen T, Bendtzen K, Nerup J, Dinarello CA, Svenson M, Nielsen JH. Affinity-purified human interleukin 1 is cytotoxic to isolated islets of Langerhans. *Diabetologia* 1986; 29: 63-67.
94. Bendtzen K. Cellekooperation ved immunrespons. ALK Symposium om Allergi (Lassen AR,ed.). Allergologisk Laboratorium A/S. København 1986; 23-28.(Review).
95. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M. Human pI 7 interleukin 1 is cytotoxic for pancreatic islets of Langerhans. *Science* 1986; 232: 1545-1547.
96. Bendtzen K. Vigtigt nyt om immunsygdomme. *Forskningen & Samfundet* 1986; 2: 10-13.
97. Bendtzen K, Barington T, Mandrup-Poulsen T, Pedersen JG, Svenson M. Measurement of human IL-1 by LIF induction, pancreatic islet-cell cytotoxicity, and bone resorption. *Lymphokine Res* 1986; 5,Suppl.1: S93-S98. (Review).
98. Mandrup-Poulsen T, Bendtzen K, Nerup J, Egeberg J, Nielsen JH. Mechanisms of pancreatic islet cell destruction. *Allergy* 1986; 41: 250-259.
99. Theander TG, Bygbjerg IC, Jepsen S, Svenson M, Kharazmi A, Larsen PB, Bendtzen K. Proliferation induced by Plasmodium falciparum antigen and interleukin-2 production by lymphocytes isolated from malaria immune individuals. *Infect Immun* 1986; 53: 221-225.
100. Bendtzen K, Werdelin O. Immunsystemets celleinteraktioner og regulatoriske mekanismer. *Basal og Klinisk Immunologi* (Bendixen G, red.). FADL's Forlag. København 1986; 114-128. (Chapter in Book).
101. Bendixen G, Weeke B, Wiik A, Svehag S.-E., Bendtzen K. Immunpatogenese. *Basal og Klinisk Immunologi* (Bendixen G, red.). FADL's Forlag. København 1986; 137-176. (Chapter in Book).
102. Bendtzen K, Andersen V. Immunterapi. *Basal og Klinisk Immunologi* (Bendixen G, red.). FADL's Forlag. København 1986; 352-364. (Chapter in Book).
103. Spinass G, Mandrup-Poulsen T, Mølviig J, Bæk L, Bendtzen K, Dinarello CA, Nerup J. Low concentrations of interleukin-1 stimulate insulin-release from isolated rat islets of Langerhans. *Acta Endocrinol* 1986; 113: 551-558
104. Rasmussen ÅK, Feldt-Rasmussen U, Bech K, Poulsen S, Bendtzen K. The influence of interleukin-1 on the function of human thyroid cells. *Proceedings of The International Symposium on Thyroid Autoimmunity*. Pisa, Italy. Nov. 24-26, 1986. *Thyroid Autoimmunity* (Pinchera A, Ingbar SH, McKenzie JM, Fenzi GF (eds). Plenum Press. New York and London 1987; pp. 327-329.

105. Heegaard PMH, Bendtzen K. Mouse acute-phase proteins: Induction by recombinant human interleukin 1. *Prot. Biol. Fluids* 1986; 34: 239-242.
106. Nielsen JH, Mandrup-Poulsen T, Spinass GA, Hansen BS, Mølviig J, Nerup J, Bendtzen K. Possible role of interleukin-1 (IL-1) in the pathogenesis of insulin-dependent diabetes mellitus (IDDM). *Excerpta Med Int Congr Ser* 1986; 717: 95-103. (Review).
107. Enk C, Oxholm P, Tvede N, Bendtzen K. Blood mononuclear cells in patients with primary Sjogren's syndrome: Production of interleukins, enumeration of interleukin-2 receptors, and DNA synthesis. *Scand J Rheumatol* 1986; Suppl 61: 131-134.
108. Bendtzen K. Ciklosporin. *Med. Årbog. (Vejlsgaard R, red.)*. Munksgaard, København 1987; 103-113. (Review).
109. Bendtzen K, Rasmussen ÅK, Bech K, Feldt-Rasmussen U. Activated T-lymphocyte subsets in Graves' disease. *N Engl J Med* 1987; 317: 247-248.
110. Bendtzen K, Rasmussen ÅK, Bech K, Feldt-Rasmussen U, Egeberg J. Cytokines in autoimmunity. *Immunol Today* 1987; 8: 203-204.
111. Mandrup-Poulsen T, Egeberg J, Nerup J, Bendtzen K, Nielsen JH, Dinarello CA. Ultrastructural studies of time-course and cellular specificity of interleukin-1 mediated islet cytotoxicity. *Acta Path Microbiol Immunol Scand Sect C* 1987; 95: 55-63.
112. Mandrup-Poulsen T, Spinass GA, Prowse SJ, Hansen BS, Jørgensen DW, Bendtzen K, Nielsen JH, Nerup J. Islet cytotoxicity of interleukin-1. Influence of culture conditions and islet donor characteristics. *Diabetes* 1987; 36: 641-647.
113. Rasmussen ÅK, Bech K, Feldt-Rasmussen U, Poulsen S, Siersbæk-Nielsen K, Friis T, Bendtzen K. The influence of interleukin-1 on the function of in vitro cultured human thyroid cells in monolayers. *Acta Endocrinol (Copenhagen)* 1987; Suppl 281: 93-95.
114. Bendtzen K. Makrofaghormonerne interleukin 1 (IL-1) og tumornekrotiserende faktor (TNF). *Ugeskr Læg* 1987; 149: 2191-2196. (Review).
115. Pedersen BK, Kharazmi A, Theander TG, Ødum N, Andersen V, Bendtzen K. Selective modulation of the CD4 molecular complex by *Pseudomonas aeruginosa* alkaline protease and elastase. *Scand J Immunol* 1987; 26: 91-94.
116. Bendtzen K. Interleukin 1 and tumor necrosis factor: Prototypes of macrophage hormones. Highlights on Endocrinology (Christiansen C, Riis BJ, eds.). Proceedings of the First European Congress on Endocrinology, Copenhagen, June 21-25, 1987; 291-300. (Review).
117. Bendtzen K. Non-immunoglobulin peptide mediators of immune responses. Highlights on Endocrinology (Christiansen C, Riis BJ, eds.). Proceedings of the First European Congress on Endocrinology, Copenhagen, June 21-25, 1987; 301-308. (Review).
118. Bygbjerg IC, Svenson M, Theander TG, Bendtzen K. Effect of antimalarial drugs on stimulation and interleukin 2 production of human lymphocytes. *Int J Immunopharmacol* 1987; 9: 513-19.
119. Mandrup-Poulsen T, Bendtzen K, Dinarello CA, Nerup J. Human tumor necrosis factor potentiates human interleukin-1 mediated rat pancreatic beta-cell cytotoxicity. *J Immunol* 1987; 139: 4077-4082.
120. Bendtzen K, Christensen LD, Fomsgaard A, Hørding M, Pedersen BK, Reimert C, Svenson M, Theander T, Tvede N, Faber V. Cytokiner (immunhormoner) og AIDS-relateret forskning. AIDS-forskning i Danmark. Statens Lægevidenskabelige Forskningsråd. Forskningsdirektoratet 1988; p. 82-88 (Minireview).
121. Hviid L, Reimert CM, Theander TG, Jepsen S, Bendtzen K. Recombinant human tumour necrosis factor is not inhibitory to *Plasmodium falciparum* in vitro. *Transact Roy Soc Trop Med Hyg.* 1988; 82: 48-49.
122. Fomsgaard A, Worsaae H, Bendtzen K. Detection of tumour necrosis factor from lipopolysaccharide-stimulated human mononuclear cells by enzyme-linked immunosorbent assay and cytotoxicity bioassay. *Scand J Immunol* 1988; 27: 143-147.
123. Oxholm A, Oxholm P, Staberg B, Bendtzen K. Immunohistological detection of interleukin 1-like molecules and tumour necrosis factor in human epidermis before and after UVB-irradiation in vivo. *Br J Dermatol* 1988; 118: 369-376.

124. Kharazmi A, Nielsen H, Bendtzen K. Recombinant interleukin 1alpha and beta prime human monocyte superoxide production but have no effect on chemotaxis and oxidative burst response of neutrophils. *Immunobiol* 1988; 177: 32-39.
125. Müller K, Svenson M, Bendtzen K. 1alpha,25-dihydroxyvitamin D3 and a novel vitamin D analogue MC 903 are potent inhibitors of human interleukin 1 in vitro. *Immunol Lett* 1988; 17: 361-366.
126. Bendtzen K, Rasmussen ÅK, Bech K, Feldt-Rasmussen U, Buschard K. Pathogenic role of interleukin 1 and tumor necrosis factor in autoimmune endocrine diseases. *Clin Immunol Newslett* 1988; 9: 72-74.(Review).
127. Svenson M, Bendtzen K. Interleukin 1-inhibitor in normal human urine: Different effects on mouse thymocytes and on a murine T-cell line. *Scand J Immunol* 1988; 27: 593-599.
128. Tvede N, Christensen LD, Ødum N, Wiik A, Bendtzen K. Interleukin 1-induced down-regulation of antibody-binding to CD4 molecules on human lymphocytes. *Scand J Immunol* 1988; 27: 679-684.
129. Eizirik DL, Strandell E, Bendtzen K, Sandler S. Functional characteristics of rat pancreatic islets maintained in culture after exposure to human interleukin 1. *Diabetes* 1988; 37: 916-919.
130. Pedersen BK, Tvede N, Hansen FR, Andersen V, Bendix T, Bendixen G, Bendtzen K, Galbo H, Haahr PM, Klarlund K, Sylvest J, Thomsen BS, Halkjær-Kristensen J. Modulation of natural killer cell activity in peripheral blood by physical exercise. *Scand J Immunol* 1988; 27: 673-678.
131. Mandrup-Poulsen T, Bendtzen K, Dinarello CA, Nerup J. Potentiating effects of tumor necrosis factor on interleukin-1 mediated pancreatic beta-cell toxicity. *Progr Leuk Biol* 1988; 8: 291-295.
132. Theander TG, Kharazmi A, Pedersen BK, Christensen LD, Tvede N, Poulsen LK, Ødum N, Svenson M, Bendtzen K. Inhibition of human lymphocyte proliferation and cleavage of interleukin-2 by *Pseudomonas aeruginosa* proteases. *Infection Immunity* 1988; 56: 1673-1677.
133. Rasmussen ÅK, Bech K, Feldt-Rasmussen U, Poulsen S, Holten I, Ryberg M, Dinarello CA, Siersbæk-Nielsen K, Friis T, Bendtzen K. Interleukin-1 affects the function of cultured human thyroid cells. *Allergy* 1988; 43: 435-441.
134. Bendtzen K. *Immunsystemet - Det Indre Forsvar*. NYSYN. Munksgaard/Chaos I/S, København, 1988. (Book/Monography).
135. Bendtzen K. Farmaceutisk præparat. Dansk Patentansøgning nr. 6039/88 indleveret 28/10-88. (Patent).
136. The Canadian-European Randomized Control Trial Group, incl. Bendtzen K. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. *Diabetes* 1988; 37: 1574-1582.
137. Bouchelouche P.N., Reimert C, Bendtzen K. Effects of natural and recombinant interleukin-1alpha and -beta on cytosolic free calcium in human and murine fibroblasts. *Leukemia* 1988; 2: 691-696.
138. Kharazmi A, Nielsen H, Bendtzen K. Modulation of human neutrophil and monocyte chemotaxis and superoxide responses by recombinant TNF-alpha and GM-CSF. *Immunobiology* 1988; 177: 363-370.
139. Bendtzen K. Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity. *Immunol Lett* 1988; 19: 183-192.(Review).
140. Bendtzen K, Morling N, Fomsgaard A, Svenson M, Jakobsen B, Ødum N, Svejgaard A. Association between HLA-DR2 and production of tumour necrosis factor alpha and interleukin 1 by mononuclear cells activated by lipopolysaccharide. *Scand J Immunol* 1988; 28: 599-606.
141. Bendtzen K. Immune hormones (cytokines). Pathogenic role in autoimmune rheumatic diseases and endocrine diseases. *Autoimmunity* 1989; 2: 177-189.(Review).
142. Fomsgaard A, Zhang G-H, Shand GH, Bendtzen K, Bæk L. Immunochemical and biological reactivity of human anti-LPS IgG for intravenous administration obtained by screening of blood donors. *Scand J Immunol* 1989; 29: 309-316.
143. Svenson M, Poulsen LK, Fomsgaard A, Bendtzen K. IgG autoantibodies against interleukin 1alpha in sera of normal individuals. *Scand J Immunol* 1989; 29: 489-492.

144. Sandler S, Bendtzen K, Borg LAH, Eizirik DL, Strandell E, Welsh N. Studies on the mechanisms causing inhibition of insulin secretion in rat pancreatic islets exposed to human interleukin-1beta indicate a perturbation in the mitochondrial function. *Endocrinology* 1989; 124: 1492-1501.
145. Bendtzen K, Svenson M, Fomsgaard A, Poulsen LK. Native inhibitors (autoantibodies) of IL-1alpha and TNF. *Immunol. Today* 1989; 10: 222.
146. Kharazmi A, Nielsen H, Rechnitzer C, Bendtzen K. Interleukin 6 primes human neutrophil and monocyte oxidative burst response. *Immunol Lett* 1989; 21: 177-184.
147. Oxholm A, Oxholm P, Staberg B, Bendtzen K. Interleukin-6 in the epidermis of patients with psoriasis before and during PUVA treatment. *Acta Derm Venerol* 1989; 69: 195-199.
148. Oxholm A, Oxholm P, Permin H, Bendtzen K. Epidermal tumour necrosis factor alpha and interleukin 6-like activities in AIDS-related Kaposi's sarcoma. *APMIS* 1989; 97: 533-538.
149. Fugger L, Morling N, Bendtzen K, Ryder L, Ødum N, Georgsen J, Svejgaard A. MspI polymorphism in the human interleukin 6 (IL 6) gene. *Nucl Acids Res* 1989; 17: 4419.
150. Fomsgaard A, Svenson M, Bendtzen K. Auto-antibodies to tumour necrosis factor alpha in healthy humans and patients with inflammatory diseases and Gram-negative bacterial infections. *Scand J Immunol* 1989; 30: 219-223.
151. Hofmann B, Langhoff E, Lindhardt BO, Ødum N, Hyldig-Nielsen JJ, Ryder LP, Platz P, Jakobsen BK, Bendtzen K, Jacobsen N, Lerche B, Schafer C, Dickmeiss E, Ulrich K, Svejgaard A. Investigation of immunosuppressive properties of inactivated human immunodeficiency virus and possible neutralization of this effect by patient sera. *Cell. Immunol.* 1989; 121: 336-348.
152. Bendtzen K, Buschard K, Diamant M, Horn T, Svenson M, The Thyroid Cell Group. Possible role of IL-1, TNFalpha and IL-6 in insulin-dependent diabetes mellitus and autoimmune thyroid disease. *Lymphokine Res* 1989; 8: 335-340.
153. Eizirik DL, Sandler S, Hallberg A, Bendtzen K, Sener A, Malaisse WJ. Differential sensitivity to beta-cell secretagogues in rat pancreatic islets exposed to human interleukin-1beta. *Endocrinology* 1989; 125: 752-759.
154. Fugger L, Bendtzen K, Morling N, Ryder L, Svejgaard A. Possible correlation of TNFalpha-production with -RFLP in humans. *Eur J Haematol* 1989; 43: 255-256.
155. Sandler S, Bendtzen K, Eizirik DL, Sjöholm Å, Welsh N. Decreased cell replication and polyamine content in insulin-producing cells after exposure to human interleukin 1beta. *Immunol Lett* 1989; 22: 267-272.
156. Svenson M, Bendtzen K. Human urine deoxyribonuclease increases endogenous thymidine in the mouse thymocyte interleukin 1 assay: An artificial interleukin 1 inhibitor. *Cytokine* 1989; 1: 52-55.
157. Bendtzen K. Det terminologiske Babelstår indenfor områderne lymfokiner og interleukiner (cytokiner). *Ugeskr Læg* 1989; 151: 2953-54 (Editorial/Minireview).
158. Mortensen SA, Bendtzen K, Andersen V, Baandrup U. Treatment of myocarditis and polymyositic heart disease guided by endomyocardial biopsy. *Concepts Immunopathol* 1989; 7: 173-195. (Review).
159. Fugger L, Morling N, Bendtzen K, Ryder LP, Svejgaard A. Bgl II polymorphism in the human interleukin 6 (IL 6) gene. *Nucl Acids Res* 1989; 17: 7548.
160. Oxholm A, Oxholm P, Staberg B, Bendtzen K. Expression of interleukin-6-like molecules and tumour necrosis factor after topical treatment of psoriasis with a new vitamin D analogue (MC 903). *Acta Derm Venerol* 1989; 69: 385-390.
161. Buschard K, Aaen K, Horn T, Van Damme J, Bendtzen K. Interleukin 6: a functional and structural in vitro modulator of beta-cells from islets of Langerhans. *Autoimmunity* 1990; 5: 185-194.
162. Bendtzen K. Kakektin - en magtfuld dræber og et uundværligt hormon. *Forskn Samfundet* 1990; 16: 8-11.
163. Bendtzen K, Svenson M, Jønsson V, Hippe E. Autoantibodies to cytokines - friends or foes? *Immunol Today* 1990; 11: 167-169 (Review/Hypothesis)
164. Sandler S, Bendtzen K, Eizirik DL, Welsh M. Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. *Endocrinology* 1990; 126: 1288-1294.

165. Pedersen M, Permin H, Bendtzen K, Norn S. Cytokine-induced release of histamine from basophil leukocytes from AIDS patients. *Agents Actions* 1990; 30: 294-296.
166. Rasmussen ÅK, Kayser L, Bech K, Feldt-Rasmussen U, Perrild H, Bendtzen K. Differential effects of interleukin 1alpha and 1beta on cultured human and rat thyroid epithelial cells. *Acta Endocrinol* 1990; 122: 520-526.
167. Bendtzen K, Svenson M, Jönsson V, Hippe E. What is the function of autoantibodies to cytokines? Reply. *Immunol Today* 1990; 11: 231.
168. Bendtzen K. A role of immunoinflammatory hormones (cytokines) in insulin-dependent diabetes mellitus? *Scand J Clin Lab Invest* 1990; 50, Suppl 202: 163-167.
169. Mandrup-Poulsen TR, Mølvig JC, Andersen V, Bendtzen K, Binder C, Brøns M, d'Amore FA, Dieperink H, Enk B, Frandsen NE, Haase H, Hey H, Juul J, Karstoft E, Kemp E, Laursen HB, Mogensen EF, Nerup J, Petersen KE, Petersen P, Roin JA, Sagild U, The Canadian-European Randomized Control Trial Group. Immunosuppression med ciklosporin inducerer klinisk remission og forbedret b-celle funktion hos patienter med nykonstateret insulin-krævende diabetes. En national og international multicenterundersøgelse. *Ugeskr Læg* 1990; 152:1963-1969.
170. Bendtzen K. New knowledge of the hormones of the immune system provides increased possibilities for treatment. *Rigshospitalets Årsberetning*. 1990.
171. Hviid L, Theander TG, Jakobsen PH, Abu-Zeid YA, Abdulhadi NH, Saeed BO, Jepsen S, Bayoumi RAL, Bendtzen K, Jensen JB. Cell-mediated immune responses to soluble *Plasmodium falciparum* antigens in residents from an area of unstable malaria transmission in the Sudan. *APMIS* 1990; 98: 594-604.
172. Remvig L, Thomsen BS, Baek L, Svenson M, Bendtzen K. Interleukin 1, but not interleukin 1 inhibitor, is released from human monocytes by immune complexes. *Scand J Immunol* 1990; 32: 255-261.
173. Müller K, Oxholm P, Sørensen OH, Thymann M, Høier-Madsen M, Bendtzen K. Abnormal vitamin D3 metabolism in patients with primary Sjögren's syndrome. *Ann Rheum Dis* 1990; 49: 682-684.
174. Fomsgaard A, Freudenberg MA, Bendtzen K, Galanos C. Quantitation and biological activities of native tumour necrosis factor from LPS stimulated human monocytes. *APMIS* 1990; 98: 529-534.
175. Bendtzen K, Svenson M, Fomsgaard A, Poulsen LK, Hansen MB. Auto-antibodies to IL-1alpha and TNFalpha in normal individuals and in infectious and immunoinflammatory disorders. *The Physiological and Pathological Effect of Cytokines*. (eds.: Powanda, Oppenheim, Kluger, Dinarello), pp. 447-452. Wiley-Liss, Inc. 1990. (Review).
176. Fugger L, Morling N, Bendtzen K, Ryder L, Andersen V, Heilmann C, Pedersen F.K., Friis J, Halberg P, Svejgaard A. IL-6 gene polymorphism in rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, systemic lupus erythematosus, and in healthy danes. *J Immunogenetics* 1990; 16: 461-465.
177. Rasmussen ÅK, Kayser L, Bech K, Bendtzen K, Feldt-Rasmussen U, Perrild H. Differential effect of interleukin-1b on cultured rat and human thyroid cells. In: Ambesi-Impimbato F, Perrild H, editors. *FRTL-5 Today*. Amsterdam: Elsevier, 1989:213-214.
178. Sandler S, Bendtzen K, Eizirik DL, Strandell E, Welsh M, Welsh N. Metabolism and beta-cell function of rat pancreatic islets exposed to human interleukin-1beta in the presence of a high glucose concentration. *Immunol Lett* 1990; 26: 245-252.
179. Svenson M, Bagge Hansen M, Bendtzen K. Distribution and characterization of autoantibodies to interleukin 1alpha in normal human sera. *Scand J Immunol* 1990; 32: 695-701.
180. Feldt-Rasmussen B, Jensen T, Dieperink H, Mandrup-Poulsen T, Nerup J, Bendtzen K, Andersen V, Kemp E, Leyssac PP. Nephrotoxicity of cyclosporin A in patients with newly diagnosed type 1 diabetes mellitus. *Diab Med* 1990; 7: 429-433.
181. Oxholm P, Oxholm A, Permin H, Bendtzen K. Immunohistology of skin from AIDS patients. *Developments in Medical Virology. Skin Langerhans (Dendritic) Cells in Virus Infections and AIDS*. Becker Y (ed). Kluwer Academic Publishers, New York, USA 1991. pp. 121-130. (Review).
182. Bendtzen K, Diamant M, Faber V. Fusidic acid, an immunosuppressive drug with functions similar to cyclosporin A. *Cytokine* 1990; 2: 423-429.

183. Bendtzen K. The role of monokines and lymphokines (cytokines) in the immune system. *Adv Clin Oncol* 1989; 3: 21-34. (Review).
184. Bouchelouche PN, Bendtzen K, Bak S, Nielsen OH. Recombinant human tumour necrosis factor increases cytosolic free calcium in murine fibroblasts and stimulates inositol phosphate formation in L-M and arachidonic acid release in 3T3 cells. *Cell Signal* 1990; 2: 479-487.
185. Haahr PM, Pedersen BK, Fomsgaard A, Tvede N, Diamant M, Klarlund K, Halkjær-Kristensen J, Bendtzen K. Effect of physical exercise on in vitro production of interleukin 1, interleukin 6, tumour necrosis factor- α , interleukin 2 and interferon- γ . *Int J Sports Med* 1991; 12:223-227.
186. Bendtzen K. *Immunsystemet*. Medicinsk Årbog. Munksgaards Forlag. København. 1991. pp. 57-66 (Review in Danish).
187. Welsh N, Bendtzen K, Sandler S. Influence of protease on inhibitory and stimulatory effects of interleukin 1 β on beta-cell function. *Diabetes* 1991; 40: 290-294.
188. Pedersen M, Permin H, Bindslev-Jensen C, Bendtzen K, Norn S. Cytokine-induced histamine release from basophils of AIDS patients. Interaction between cytokines and specific IgE antibodies. *Allergy* 1991; 46: 129-134.
189. Oxholm A, Diamant M, Oxholm P, Bendtzen K. Interleukin-6 and tumour necrosis factor alpha are expressed by keratinocytes but not by Langerhans cells. *APMIS* 1991; 99: 58-64.
190. Bendtzen K, Vesti-Nielsen N, Petersen J, Andersen V, Bendixen G. Treatment of chronic endogenous uveitis with fusidic acid. *Lancet* 1991; 337: 552-553 (letter).
191. Oxholm A, Oxholm P, Avnstorp C, Bendtzen K. Keratinocyte-expression of interleukin-6 but not of tumour necrosis factor- α is increased in the allergic and the irritant patch test reaction. *Acta Derm Venereol* 1991; 71: 93-98.
192. Bendtzen K. *Immunsystemet - ven eller fjende*. *Farmac* 1991; 3:72-73. (Review in Danish).
193. Hansen MB, Svenson M, Diamant M, Bendtzen K. Anti-interleukin-6 antibodies in normal human serum. *Scand J Immunol* 1991; 33:777-781.
194. Svenson M, Kayser L, Hansen MB, Rasmussen ÅK, Bendtzen K. Interleukin-1 receptors on human thyroid cells and on the rat thyroid cell line FRTL-5. *Cytokine* 1991; 3:125-130.
195. Welsh N, Welsh M, Lindquist S, Eizirik DL, Bendtzen K, Sandler S. Interleukin-1 β increases the biosynthesis of the heat shock protein hsp70 and selectively decreases the biosynthesis of five proteins in rat pancreatic islets. *Autoimmunity* 1991; 9:33-40.
196. Eizirik DL, Bendtzen K, Sandler S. Short exposure of rat pancreatic islets to interleukin-1 β induces a sustained but reversible impairment in b-cell function: Influence of protease activation, gene transcription and protein synthesis. *Endocrinology* 1991; 128:1611-1616.
197. Jensen HS, Tvede N, Diamant M, Mogensen HH, Hansen MB, Thomsen BS, Pedersen PB, Bendtzen K. Elastolytic activity of human monocytes from synovial fluid and blood of patients with arthritis. Relations to levels of interleukin 6 and soluble interleukin 2 receptor. *Scand J Rheumatol* 1991; 20:83-90.
198. Møller B, Mogensen SC, Wendelboe P, Bendtzen K, Petersen CM. Bioactive and inactive forms of tumor necrosis factor- α in spinal fluid from patients with meningitis. *J Infect Dis* 1991; 163:886-889.
199. Reimert CM, Venge P, Kharazmi A, Bendtzen K. Detection of eosinophil cationic protein (ECP) by an enzyme-linked immunosorbent assay. *J Immunol Methods* 1991; 138:285-290.
200. Eizirik DL, Tracey DE, Bendtzen K, Sandler S. An interleukin-1 receptor antagonist protein protects insulin-producing beta cells against suppressive effects of interleukin-1 β . *Diabetologia* 1991; 34:445-448.
201. Müller K, Heilmann C, Poulsen LK, Barington T, Bendtzen K. The role of monocytes and T cells in 1,25-dihydroxyvitamin D3 mediated inhibition of B cell function in vitro. *Immunopharmacology* 1991; 21:121-128.
202. Langholz E, Brynskov J, Freund LG, Bendtzen K. Fusidic acid for Behcet's colitis: A novel approach to T-cell specific immunosuppressive therapy. *Dan Med Bull* 1991; 38:284.

203. Müller K, Diamant M, Bendtzen K. Inhibition of production and function of interleukin-6 by 1,25-dihydroxyvitamin D3. *Immunol Lett* 1991; 28:115-120.
204. Rasmussen ÅK, Kayser L, Bech K, Feldt-Rasmussen U, Perrild H, Bendtzen K. Influence of interleukin 6 on the function of secondary cultures of human thyrocytes. *Acta Endocrinol* 1991; 124:577-582.
205. Brynskov J, Hansen MB, Reimert C, Bendtzen K. Inhibitor of interleukin-1a and interleukin-1b-induced T-cell activation in serum of patients with active Crohn's disease. *Dig Dis Sci* 1991; 36:737-742.
206. Rasmussen ÅK, Kayser L, Feldt-Rasmussen U, Bech K, Bendtzen K, Diamant M, Perrild H. Interleukin-6 is not a second mediator of interleukin-1 induced suppression of thyroid function in cultured human thyrocytes. *Exp Clin Endocrinol* 1991; 97:179-181.
207. Reimert CM, Minuva U, Kharazmi A, Bendtzen K. Eosinophil protein X/eosinophil derived neurotoxin (EPX/EDN): Detection by enzyme linked immunosorbent assay and purification from normal human urine. *J Immunol Methods* 1991; 141:97-104.
208. Remvig L, Vibe-Petersen J, Svenson M, Enk C, Bendtzen K. Biological assays for interleukin 1 detection. Comparison of human T lymphocyte, murine thymocyte and NOB-1 assays. *Allergy* 1991; 46: 59-67.
209. Diamant M, Svenson M, Tvede N, Poulsen L, Bendtzen K, Kharazmi A. Receptor binding inhibition and inactivation of biological activity of interleukin-1 by *Pseudomonas aeruginosa* elastase. *Immunol Inf Dis* 1991; 1:183-186.
210. Müller K, Gram J, Bollerslev J, Diamant M, Barington T, Hansen MB, Bendtzen K. Down-regulation of monocyte functions by treatment of healthy adults with 1a,25 dihydroxyvitamin D3. *Int J Immunopharmacol* 1991; 13:525-530.
211. Rasmussen ÅK, Kayser L, Bech K, Feldt-Rasmussen U, Perrild H, Bendtzen K. Interleukin 6: A pathogenic factor in autoimmune thyroid diseases? In: Scherbaum WA, Bogner U, Weinheimer B, Bottazzo GF, editors. *Autoimmune Thyroiditis. Approaches towards its etiological differentiation*. Berlin: Springer-Verlag, 1991:231-234.
212. Kayser L, Rasmussen ÅK, Bech K, Feldt-Rasmussen U, Perrild H, Bendtzen K. Endotoxins do not mimic the effect of interleukin-1 in secondary cultures of human thyroid cells. In: Scherbaum WA, Bogner U, Weinheimer B, Bottazzo GF, editors. *Autoimmune Thyroiditis. Approaches towards its etiological differentiation*. Berlin: Springer-Verlag, 1991:235-237.
213. Bendtzen K. Cellular and molecular processes underlying immunoinflammation. In: Ahlstedt S, Mattson P, Thorell J, Venge P, editors. *Clinical Impact of the Monitoring of Allergic Inflammation*. London: Academic Press, 1991:187-200.(Review).
214. Jensen HS, Jensen LT, Saxne T, Diamant M, Bendtzen K. Human monocyte elastolytic activity, the propeptides of types I and III procollagen, proteoglycans, and interleukin-6 in synovial fluid from patients with arthritis. *Clin Exp Rheumatol* 1991; 9:391-394.
215. Hansen MB, Svenson M, Bendtzen K. Human anti-interleukin 1a antibodies. *Immunol Lett* 1991; 30:133-140.
216. Bendtzen K. Molecular biology of macrophage hormones (cytokines) and their interaction with endocrine systems. *Folia Endocrinol Japonica* 1991; 67:872-877.(Review).
217. Bendtzen K. Feber og akut-fase reaktionen som led i det cytokinmedierede cellesprog. *Ugeskr Læg* 1991; 153:3534-3535 (Editorial / Review).
218. Welsh N, Eizirik DL, Bendtzen K, Sandler S. Interleukin-1b-induced nitric oxide production in isolated rat pancreatic islets requires gene transcription and may lead to inhibition of the krebs cycle enzyme aconitase. *Endocrinology* 1991; 129:3167-3173.
219. Bendtzen K. Why is too little TNF bad? *Cytokine* 1991; 3:636-637.
220. Bendtzen K, Diamant M, Horn T, Pedersen C, Buschard K. Effect of fusidic acid on interleukin-1 (IL-1)- and IL-6-induced pancreatic b-cell functions in rats. *J Endocrinol* 1992; 132:345-352.
221. Bendtzen K. Clinical significance of cytokines. Natural and therapeutic regulation. *Sem Clin Immunol* 1991; 3:5-13.(Review).

222. Christensen LD, Andersen V, Nygaard P, Bendtzen K. Effects of immunomodulators on ecto-5'-nucleotidase activity on blood mononuclear cells in vitro. *Scand J Immunol* 1992; 35:407-413.
223. Svenson M, Hansen MB, Kayser L, Rasmussen ÅK, Reimert CM, Bendtzen K. Effects of human anti-IL-1a autoantibodies on receptor binding and biological activities of IL-1. *Cytokine* 1992; 4:125-133.
224. Hansen MB, Svenson M, Bendtzen K. Serum-induced suppression of interferon (IFN) activity. Lack of evidence for the presence of specific autoantibodies to IFN α in normal human sera. *Clin Exp Immunol* 1992; 88:559-562.
225. Eizirik DL, Tracey DE, Bendtzen K, Sandler S. Role of receptor binding and gene transcription for both the stimulatory and inhibitory effects of interleukin-1 in pancreatic b-cells. *Autoimmunity* 1992; 12:127-133.
226. Oxholm P, Daniels TE, Bendtzen K. Cytokine expression in labial salivary glands from patients with primary Sjögren's syndrome. *Autoimmunity* 1992; 12:185-191.
227. Kjaer TW, Rygaard J, Bendtzen K, Josefsen K, Bock T, Buschard K. Interleukins increase surface ganglioside expression of pancreatic islet cells in vitro. *APMIS* 1992; 100:509-514.
228. Martin S, Pawlowski B, Greulich B, Ziegler AG, Mandrup-Poulsen T, Mahon J. Natural course of remission in IDDM during 1st yr after diagnosis. *Diab Care* 1992; 15:66-74. (group authorship)
229. Müller K, Pedersen FK, Wiik A, Bendtzen K. Lymphokines and soluble interleukin-2 receptors in juvenile chronic arthritis. Clinical and laboratory correlations. *Rheumatol Int* 1992; 12:89-92.
230. Kristensen KS, Bendtzen K, Norn S, Skov PS, Pedersen M, Permin H. Cytokines modulate IgE-mediated histamine liberation from human basophils. A comparative study of IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-6, TNF, LT, IFN α , IFN γ , GM-CSF and M-CSF. *Agents Actions* 1992; C260-C264.
231. Bendtzen K. Three suggestions for involvement of immunoinflammatory peptides (cytokines) in the pathogenesis of multiple sclerosis. In: Haahr S, editor. Conference Report. Second International Symposium on Retrovirus in Multiple Sclerosis and Related Diseases. 26-28 August 1991, Copenhagen, Denmark. *J. Neuroimmunol.*, 1992: pp. 168-169.
232. Langholz E, Brynskov J, Bendtzen K, Vilien M, Binder V. Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin. *Aliment Pharmacol Ther* 1992; 6:495-502.
233. Bendtzen K, Hansen MB, Diamant M, Heegaard P, Svenson M. Cytokine regulation during inflammation: modulation by autoantibodies and fever. In: Bartfai T, Ottoson D, editors. *Neuro-Immunology of Fever*. Oxford. Pergamon Press, 1992. pp. 215-224.
234. Müller K, Rieneck K, Hansen MB, Bendtzen K. 1,25-dihydroxyvitamin D₃-mediated suppression of T lymphocyte functions and failure of T cell-activating cytokines to restore proliferation. *Immunol Lett* 1992; 34:37-44.
235. Poulsen LK, Baron L, Heinig JH, Skov PS, Bendtzen K. Biomolecular regulation of the IgE immune response. I. Cell-associated IgE and in vitro IgE synthesis. *Allergy* 1992; 47:560-567.
236. Brynskov J, Nielsen OH, Ahnfelt-Rønne I, Bendtzen K. Review: Cytokines in inflammatory bowel disease. *Scand J Gastroenterol* 1992; 27:897-906. (Review).
237. Kristensen KS, Bendtzen K, Skov PS, Pedersen M, Permin H, Norn S. Modulation of IgE-mediated basophil histamine release by various cytokines. *Pneumon Alergol Polska* 1992; 60, Suppl. 2:70-73.
238. Buschard K, Pedersen C, Hansen SV, Hageman I, Aaen K, Bendtzen K. Anti-diabetogenic effect of fusidic acid in diabetes prone BB rats. *Autoimmunity* 1992; 14:101-104.
239. Müller K, Haahr PM, Diamant M, Rieneck K, Kharazmi A, Bendtzen K. 1,25-dihydroxyvitamin D₃ inhibits cytokine production by human blood monocytes at the post-transcriptional level. *Cytokine* 1992; 4:506-512.
240. Bendtzen K, Hansen MB, Svenson M. Immunoinflammatory mediators (cytokines) in trauma. Natural regulation and intervention with systemic complications. In: Borris LC, Lassen MR, Bergqvist D, editors. *The Traumatized Patient - with Special Reference to Systemic Complications*. Aalborg, Denmark: The Venous Thrombosis Group, 1992: pp. 135-144. (Review).
241. Müller K, Bendtzen K. Inhibition of human T lymphocyte proliferation and cytokine production by 1,25-dihydroxyvitamin D₃. Differential effects on CD45RA⁺ and CD45R0⁺ cells. *Autoimmunity* 1992; 14:37-43.

242. Nicoletti F, Meroni PL, Grasso S, Di Marco R, Barcellini W, Gozzo G, Bendtzen K. Efficacia immunosoppressiva "in vivo" dell'acido fusidico (A.F.) nel ratto BB. Atti XII Congresso della Societa' Italiana di Immunologia e Immunopathologia Gia 1992; 360-365.
243. Hansen MB, Svenson M, Diamant M, Bendtzen K. High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. *Cytokine* 1993; 5:72-80.
244. Nielsen OH, Brynskov J, Bendtzen K. Circulating and mucosal concentrations of tumour necrosis factor and inhibitor(s) in chronic inflammatory bowel disease. *Dan Med Bull* 1993; 40:247-249.
245. Müller K, Ødum N, Bendtzen K. 1,25-Dihydroxyvitamin D3 selectively reduces interleukin-2 levels and proliferation of human T cell lines in vitro. *Immunol Lett* 1993; 35:177-182.
246. Tønnesen E, Wanscher M, Höhndorf K, Bendtzen K, Hansen MB, Diamant M, Hansen GL, Toft P. Effect of methylprednisolone on the cytokine response in patients undergoing lung surgery. *Acta Anaesthesiol Scand* 1993; 37:410-414.
247. Kemp M, Kurtzhals JAL, Bendtzen K, Poulsen LK, Hansen MB, Koech DK, Kharazmi A, Theander TG. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. *Infect Immun* 1993; 61:1069-1073.
248. Kronborg G, Hansen MB, Svenson M, Fomsgaard A, Høiby N, Bendtzen K. Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. *Ped Pulmonol* 1993; 15:292-297.
249. Reimert CM, Ouma JH, Mwanje MT, Magak P, Poulsen LK, Vennervald BJ, Christensen N, Kharazmi A, Bendtzen K. Indirect assessment of eosinophiluria in urinary schistosomiasis using eosinophil cationic protein (ECP) and eosinophil protein X (EPX). *Acta Trop*. 1993; 54:1-12.
250. Andersen A, Pedersen H, Bendtzen K, Röpke C. Effects of growth factors on cytokine production in serum-free cultures of human thymic epithelial cells. *Scand J Immunol* 1993; 38:233-238.
251. Laham N, Rice GE, Bishop GJ, Hansen MB, Bendtzen K, Brennecke SP. Elevated plasma interleukin 6: A biochemical marker of human preterm labour. *Gynecol Obstet Invest* 1993; 36:145-147.
252. Bendtzen K. The polypeptide mediator network of the immune system. Clinical significance in traumatic, infectious and autoimmune diseases. In: Ullman U, Dalhoff A, editors. *Significance of Cytokines in the Treatment of Infectious Diseases*. Gustav Fischer Verlag, Stuttgart, 1993. pp. 97-110. (Review).
253. Feldt-Rasmussen U, Rasmussen ÅK, Kayser L, Svenson M, Diamant M, Bech K, Bendtzen K. A role of interleukin-1 and interleukin-6 in thyroiditis? In: Nagataki S, Mori T, Torizuka K, editors. *80 Years of Hashimotos Disease*. Amsterdam: Elsevier Science Publishers, 1993: pp. 313-318.
254. Rieneck K, Diamant M, Haahr P-M, Schönharting M, Bendtzen K. In vitro immunomodulatory effects of pentoxifylline. *Immunol Lett* 1993; 37:131-138.
255. Svenson M, Hansen MB, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. *J Clin Invest* 1993; 92:2533-2539.
256. Bendtzen K, Hansen MB, Svenson M. Modulation of inflammatory cytokines by a receptor antagonist, autoantibodies, and fever. In: Garaci E, Goldstein AL, editors. *Combination Therapies 2: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases*. New York: Plenum Press, 1993: pp. 123-134. (Review).
257. Kemp M, Kurtzhals JAL, Christensen CBV, Kharazmi A, Jardim A, Bendtzen K, Gachihi GS, Olafson RW, Theander TG. Production of interferon-gamma and interleukin-4 by human T cells recognizing Leishmania lipophosphoglycan-associated protein. *Immunol Lett* 1993; 38:137-144.
258. Tønnesen E, Hansen MB, Höhndorf K, Diamant M, Bendtzen K, Wanscher M, Toft P. Cytokines in plasma and ultrafiltrate in relation to continuous arteriovenous haemofiltration. *Anaesth Intens Care* 1993; 21:752-758.
259. Bendtzen K, Svenson M, Hansen M. Autoantibodies to cytokines in IVIG. *J Rheumatol* 1993; 20:2176-2177.
260. Svenson M, Hansen MB, Heegaard P, Abell K, Bendtzen K. Specific binding of interleukin 1 (IL-1)b and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I. *Cytokine* 1993; 5:427-435.

261. Reimert CM, Poulsen LK, Bindslev-Jensen C, Kharazmi A, Bendtzen K. Measurement of eosinophil cationic protein (ECP) and eosinophil protein X/eosinophil derived neurotoxin (EPX/EDN). *J Immunol Methods* 1993; 166:183-190.
262. Kjeldsen M, Holmstrup P, Bendtzen K. Marginal periodontitis and cytokines. A review of the literature. *J Periodontol* 1993; 64:1013-1022. (Review).
263. Rasmussen ÅK, Feldt-Rasmussen U, Bendtzen K. The effect of interleukin-1 on the thyroid gland. *Autoimmunity* 1993; 16:141-148 (Review).
264. Koch C, Pedersen FK, Bendtzen K, Ryder L. Necrotic ulceration of the nose in a patient with primary immunodeficiency syndrome characterized by severe defects in the production of cytokines. *Immunodeficiency* 1993; 4:141-144.
265. Nicoletti F, Di Marco R, Morrone S, Zaccone P, Lembo D, Grasso S, Santoni A, Meroni PL, Bendtzen K. Reduction of spontaneous autoimmune diabetes in diabetes-prone BB rats with the novel immunosuppressant fusidic acid. Effect on T-cell proliferation and production of interferon-gamma. *Immunology* 1994; 81:317-321.
266. Hansen PR, Svendsen JH, Høyer S, Kharazmi A, Bendtzen K, Haunsø S. Tumor necrosis factor- α increases myocardial microvascular transport in vivo. *Am J Physiol (Heart Circ Physiol)* 1994; 266:H60-H67.
267. Petersen J, Bendtzen K, Halberg P, Stengaard-Pedersen K. Ciclosporin i behandlingen af reumatoid arthritis: En statusrapport. København: Sandoz, 1994.
268. Hansen MB, Svenson M, Abell K, Varming K, Nielsen HP, Bertelsen A, Bendtzen K. Sex- and age-dependency of IgG autoantibodies against IL-1 α in healthy humans. *Eur J Clin Invest* 1994; 24:212-218.
269. Jakobsen PH, Morris-Jones S, Theander TG, Hviid L, Hansen MB, Bendtzen K, Ridley RG, Greenwood BM. Increased plasma levels of soluble IL-2R are associated with severe *Plasmodium falciparum* malaria. *Clin Exp Immunol* 1994; 96:98-103.
270. Eizirik DL, Sandler S, Welsh N, Cetkovic-Cvrlje M, Nieman A, Geller DA, Pipeleers DG, Bendtzen K, Hellerström C. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. *J Clin Invest* 1994; 93:1968-1974.
271. Bendixen G, Bendtzen K, Marker O, Svehag S-E, Svejgaard A (eds.). Basal og klinisk immunologi. 2.udg. København: FADL's Forlag, 1994: pp. 1-479.
272. Bendtzen K, Werdelin O, Ryder LP. Celleinteraktioner og regulation. In: Bendixen G, Bendtzen K, Marker O, Svehag S-E, Svejgaard A, editors. Basal og klinisk immunologi. 2.udg. København: FADL's Forlag, 1994: pp. 111-131. (Book chapter in Danish).
273. Bendtzen K, Bendixen G, Poulsen LK, Svehag S-E, Weeke B, Wiik A. Immunpatogenese og inflammation. In: Bendixen G, Bendtzen K, Marker O, Svehag S-E, Svejgaard A, editors. Basal og klinisk immunologi. 2.udg. København: FADL's Forlag, 1994: pp. 152-201. (Book chapter in Danish).
274. Bendtzen K, Andersen V. Immunterapi. In: Bendixen G, Bendtzen K, Marker O, Svehag S-E, Svejgaard A, editors. Basal og klinisk immunologi. 2.udg. København: FADL's Forlag, 1994: pp. 384-403. (Book chapter in Danish).
275. Bendixen G, Heron I, Svejgaard A, Wiik A, Bendtzen K, Weeke B, Svehag S-E, Koch C, Werdelin O, Ryder LP, Marker O, Thomsen AR, Bro-Jorgensen K, Andersen V. Immunologiske metoder. In: Bendixen G, Bendtzen K, Marker O, Svehag S-E, Svejgaard A, editors. Basal og klinisk immunologi. 2.udg. København: FADL's Forlag, 1994: pp. 404-462. (Book chapter in Danish).
276. Bendtzen K, Bendixen G. Den inflammatoriske reaktion. In: Lorenzen I, Bendixen G, Hansen NE, editors. Medicinsk kompendium. København: Nyt Nordisk Forlag Arnold Busck, 1994: pp. 37-48. (Book chapter in Danish).
277. Bendixen G, Bendtzen K. Immunfysiologi og patogenese. In: Lorenzen I, Bendixen G, Hansen NE, editors. Medicinsk kompendium. København: Nyt Nordisk Forlag Arnold Busck, 1994: pp. 49-77. (Book chapter in Danish).

278. Bendtzen K, Andersen V. Immunmodulation. Terapeutiske principper. In: Lorenzen I, Bendixen G, Hansen NE, editors. Medicinsk kompendium. København: Nyt Nordisk Forlag Arnold Busck, 1994: pp. 103-111. (Book chapter in Danish).
279. Sandler S, Buschard K, Bendtzen K. Effects of 1,25-dihydroxyvitamin D₃ and the analogues MC 903 and KH 1060 on interleukin-1b induced inhibition of rat pancreatic islet b-cell function in vitro. *Immunol Lett* 1994; 41:73-77.
280. Rasmussen K, Nielsen H, Andersen V, Barington T, Bendtzen K, Hansen MB, Nielsen L, Pedersen BK, Wiik A. Chronic fatigue syndrome--A controlled cross sectional study. *J Rheumatol* 1994; 21:1527-1531.
281. Bendtzen K, Andersen V. Immunfarmakologi. In: Kampmann JP, Gram LF, Hansen JM, Nielsen-Kudsk F, Schou JS, editors. Basal og klinisk farmakologi. Copenhagen: FADL's Forlag, 1994: pp. 502-515. (Book chapter in Danish).
282. Nielsen M, Ødum N, Bendtzen K, Ryder LP, Jakobsen BK, Svejgaard A. MHC class II molecules regulate growth in human T cells. *Exp Clin Immunogenet* 1994; 11:23-32.
283. Bendtzen K, Hansen MB, Diamant M, Ross C, Svenson M. Naturally occurring autoantibodies to interleukin-1a, interleukin-6, interleukin-10 and interferon-a. *J Interferon Res* 1994; 14:157-158. (Review).
284. Ross C, Svenson M, Hansen MB, Vejlsgaard GL, Bendtzen K. Specific autoantibodies directed against interferon-a in pharmaceutically prepared human immunoglobulin preparations. *J Interferon Res* 1994; 14:159-160.
285. Jakobsen PH, McKay V, Morris-Jones SD, McGuire W, Van Hensbroek MB, Meisner S, Bendtzen K, Schousboe I, Bygbjerg IC, Greenwood BM. Increased concentrations of interleukin-6 and interleukin-1 receptor antagonist and decreased concentrations of beta-2-glycoprotein I in Gambian children with cerebral malaria. *Infect Immun* 1994; 62:4374-4379.
286. Welsh N, Margulis B, Bendtzen K, Sandler S. Liposomal delivery of antioxidant enzymes protects against hydrogen peroxide- but not interleukin-1b-induced inhibition of glucose metabolism in rat pancreatic islets. *J Endocrinol* 1994; 143:151-156.
287. Horn T, Bendtzen K, Hageman I, Buschard K. Morphological effects of sodium fusidate (fusidin) on pancreatic islet cells: An electron microscopic study. *Pharmacol Toxicol* 1994; 75:228-230.
288. Rasmussen ÅK, Nielsen H, Andersen V, Barington T, Bendtzen K, Hansen MB, Nielsen L, Pedersen BK, Wiik A. Kronisk træthedssyndrom - et kontrolleret tværsnitstudie. *Ugeskr Læg* 1994; 156:6836-6840.
289. Rasmussen ÅK, Kayser L, Feldt-Rasmussen U, Bendtzen K. Influence of tumour necrosis factor-a, tumour necrosis factor-b and interferon-g, separately and added together with interleukin-1b, on the function of cultured human thyroid cells. *J Endocrinol* 1994; 143:359-365.
290. Kemp M, Hey AS, Bendtzen K, Kharazmi A, Theander TG. Th1-like human T-cell clones recognizing *Leishmania gp63* inhibits *Leishmania* major infection in human macrophages. *Scand J Immunol* 1994; 40:629-635.
291. Brynskov J, Nielsen OH, Ahnfelt-Rønne I, Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel diseases (Crohn's disease and ulcerative colitis). A review. *Survey Dig Dis* 1994; 12:290-304 (Review).
292. Bendtzen K. Cytokines and natural regulators of cytokines. *Immunol Lett* 1994; 43:111-123 (Review).
293. Laham N, Brennecke SP, Bendtzen K, Rice GE. Tumour necrosis factor a during human pregnancy and labour: maternal plasma and amniotic fluid concentrations and release from intrauterine tissues. *Eur J Endocrinol* 1994; 131:607-614.
294. Eizirik DL, Sandler S, Welsh N, Bendtzen K, Hellerström C. Nicotinamide decreases nitric oxide production and partially protects human pancreatic islets against the suppressive effects of combinations of cytokines. *Autoimmunity* 1994; 19:193-198.
295. Rasmussen ÅK, Di Marco R, Diamant M, Feldt-Rasmussen U, Bendtzen K. Nitric oxide production is not involved in the effects of interleukin-1b on cAMP, thyroglobulin and interleukin-6 in TSH-stimulated human thyroid cells. *Autoimmunity* 1994; 19:239-245.

296. Diamant M, Hansen MB, Rieneck K, Svenson M, Yasukawa K, Bendtzen K. Stimulation of the B9 hybridoma cell line by soluble interleukin-6 receptors. *J Immunol Methods* 1994; 173:229-235.
297. Bendtzen K, Nielsen H, Petersen J. Behandling af reumatoid artrit med anti-TNF α antistof. *Ugeskr Læg* 1995; 157:1689-1690.
298. Kjeldsen M, Holmstrup P, Lindemann RA, Bendtzen K. Bacterial-stimulated cytokine production of peripheral mononuclear cells from patients of various periodontitis categories. *J Periodontol* 1995; 66:139-144.
299. Hansen MB, Svenson M, Abell K, Yasukawa K, Diamant M, Bendtzen K. Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors. *Eur J Immunol* 1995; 25:348-354.
300. Josefsen K, Nielsen H, Hansen WA, Kristensen JK, Bilde T, Bendtzen K, Buschard K. Tissue culture supernatants from human islets of Langerhans activate the oxidative burst response of human monocytes in vitro. *Life Sci* 1995; 56:1333-1342.
301. Poulsen LK, Reimert CM, Bindslev-Jensen C, Hansen MB, Bendtzen K. Biomolecular regulation of the IgE immune response. II. In vitro IgE synthesis and spontaneous production of cytokines. *Int Arch Allergy Immunol* 1995; 106:55-61.
302. Bendixen G, Bendtzen K. Statusartikel: Molekylærbiologi og reumatologi. *Ugeskr Læg* 1995; 157:2421-2423. (Minireview).
303. Welsh N, Bendtzen K, Welsh M. Expression of an insulin/interleukin-1 receptor antagonist hybrid gene in insulin-producing cell lines (HIT-T15 and NIT-1) confers resistance against interleukin-1-induced nitric oxide production. *J Clin Invest* 1995; 95:1717-1722.
304. Welsh M, Welsh N, Bendtzen K, Mares J, Strandell E, Öberg C, Sandler S. Comparison of mRNA contents of interleukin-1 β and nitric oxide synthase in pancreatic islets isolated from female and male nonobese diabetic mice. *Diabetologia* 1995; 38:153-160.
305. Bendtzen K, Hansen MB, Ross C, Poulsen LK, Svenson M. Cytokines and autoantibodies to cytokines. *Stem Cells* 1995; 13:206-222. (Review).
306. Ross C, Svenson M, Hansen MB, Vejlsgaard GL, Bendtzen K. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. *J Clin Invest* 1995; 95:1974-1978.
307. Hansen MB, Svenson M, Diamant M, Ross C, Bendtzen K. Interleukin-6 (IL-6) autoantibodies and blood IL-6 measurements. *Blood* 1995; 85:1145.
308. Kayser L, Broholm H, Francis D, Perrild H, Olsen BE, Bendtzen K, Høyer PE. Immunocytochemical localisation of interleukin-1 α and interleukin-6 in thyroid tissues from patients with neoplastic or autoimmune thyroid disorders. *Autoimmunity* 1995; 20:75-82.
309. Müller K, Kriegbaum NJ, Baslund B, Sorensen OH, Thymann M, Bendtzen K. Vitamin D3 metabolism in patients with rheumatic diseases: Low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. *Clin Rheumatol* 1995; 14:397-400.
310. Sternesjö J, Bendtzen K, Sandler S. Effects of prolonged exposure in vitro to interferon-gamma and tumour necrosis factor-alpha on nitric oxide and insulin production of rat pancreatic islets. *Autoimmunity* 1995; 20:185-190.
311. Jakobsen PH, Staalso T, Bendtzen K, Stürchler D. The antimalarial drug, Ro 42-1611 (arteflene), does not affect cytoadherence and cytokine-inducing properties of *Plasmodium falciparum* malaria parasites. *Trop Med Parasitol* 1995; 46:88-92.
312. Bendtzen K. Statusartikel: Molekylærbiologi og inflammation. *Ugeskr Læg* 1995; 157:4799-4802.
313. Hansen MB, Svenson M, Diamant M, Abell K, Bendtzen K. Interleukin-6 autoantibodies: possible biological and clinical significance. *Leukemia* 1995; 9:1113-1115.
314. Rødgaard A, Thomsen BS, Bendixen G, Bendtzen K. Increased expression of complement receptor type 1 (CR1, CD35) on human peripheral blood T lymphocytes after polyclonal activation in vitro. *Immunol Res* 1995; 14:69-76.

315. Nicoletti F, Zaccone P, Di Marco R, Magro G, Grasso S, Morrone S, Santoni A, Tempera G, Meroni PL, Bendtzen K. Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. *Immunology* 1995; 85:645-650.
316. Hansen MB, Andersen V, Rohde K, Florescu A, Ross C, Svenson M, Bendtzen K. Cytokine autoantibodies in rheumatoid arthritis. *Scand J Rheumatol* 1995; 24:197-203.
317. Svenson M, Nedergaard S, Heegaard PMH, Whisenand TD, Arend WP, Bendtzen K. Differential binding of human interleukin-1 (IL-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type I receptors. *Eur J Immunol* 1995; 25:2842-2850.
318. Pedersen G, Brynskov J, Nielsen OH, Bendtzen K. Adhesion molecules in inflammatory and neoplastic intestinal diseases. *Dig Dis* 1995; 13:322-336.
319. Birkeland SA, Hamilton-Dutoit S, Sandvej K, Andersen HMK, Bendtzen K, Møller B, Jørgensen KA. EBV-induced post-transplant lymphoproliferative disorder (PTLD). *Transplant Proc* 1995; 27:3467-3472.
320. Andersen LS, Petersen J, Svenson M, Bendtzen K. IgG for intravenous use, autologous serum and plasma induce comparable interleukin-1 receptor antagonist liberation from human mononuclear cells: An in vitro phenomenon depending upon plastic adherence. *Autoimmunity* 1995; 22:127-133.
321. Birkeland SA, Bendtzen K. Interleukin-10 and Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. *Transplantation* 1996; 61:1425-1426.
322. Müller K, Hansen MB, Zak M, Nielsen S, Pedersen FK, de Nully P, Bendtzen K. Autoantibodies to IL-1a in sera from umbilical cords, children, and adults, and from patients with juvenile chronic arthritis. *Scand J Rheumatol* 1996; 25:164-167.
323. Bendtzen K, Hansen MB, Ross C, Svenson M. Cytokine autoantibodies. In: Peter JB, Shoenfeld Y, editors. *Autoantibodies*. Amsterdam: Elsevier Science B.V., 1996. (Review)
324. Laham N, Brennecke SP, Bendtzen K, Rice GE. Differential release of interleukin-6 from human gestational tissues in association with labour and in vitro endotoxin treatment. *J Endocrinol* 1996; 149:431-439.
325. Diamant M, Hansen MB, Rieneck K, Svenson M, Yasukawa K, Bendtzen K. Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors. *Leuk Res* 1996; 20:291-301.
326. Müller K, Bendtzen K. 1,25-Dihydroxyvitamin D₃ as a natural regulator of human immune functions. *J Invest Dermatol* 1996; Symp Proc 1:68-71. (Review)
327. Hendel J, Brynskov J, Særmark T, Bendtzen K. Section Review: Experimental cytokine modulation therapy of inflammatory bowel disease (Crohn's disease and ulcerative colitis). *Exp Opin Invest Drugs* 1996; 5:843-850. (Review).
328. Rasmussen ÅK, Di Marco R, Diamant M, Feldt-Rasmussen U, Bendtzen K. Nitric oxide production is not involved in the effects of interleukin-1b on cAMP, thyroglobulin and interleukin-6 in TSH-stimulated human thyroid cells. *Autoimmunity* 1996; 19:328.
329. Rieneck K, Renneberg J, Gutschik E, Diamant M, Svenson M, Bendtzen K. *Staphylococcus aureus* novel antigen gene, complete cds. GenBank 1996. (ORF-1)
330. Rieneck K, Renneberg J, Diamant M, Gutschik E, Bendtzen K. Molecular cloning and expression of a novel *Staphylococcus aureus* antigen. GenBank 1996. (ORF-2)
331. Genovese F, Mancuso G, Cuzzola M, Cusumano V, Nicoletti F, Bendtzen K, Teti G. Improved survival and TNFa-antagonistic effect of sodium fusidate in a neonatal mouse model of endotoxin shock. *Antimicrob Agents Chemother* 1996; 40:1733-1735.
332. Kayser L, Broholm H, Francis D, Perrild H, Olsen BE, Bendtzen K, Høyer PE. Immunocytochemical localisation of tumor necrosis factor a in thyroid tissues from patients with neoplastic or autoimmune thyroid disorders. *Autoimmunity* 1996; 23:91-97.
333. Bendtzen K. CCC Biotechnology Center for Cellular Communication 1996; Electronic publication: <http://inet.uni2.dk/~iirrh/IIRhome.htm>.

334. Møller B, Ellermann-Eriksen S, Storgaard M, Obel N, Bendtzen K, Petersen CM. Soluble tumor necrosis factor (TNF) receptors conserve TNF bioactivity in meningitis patient spinal fluid. *J Infect Dis* 1996; 174:557-563.
335. Ullum H, Diamant M, Victor J, Gøtzsche PC, Bendtzen K, Skinhøj P, Pedersen BK. Increased circulating levels of interleukin-6 in HIV-seropositive subjects. *J Acquir Immune Defic Syndr Hum Retrovirol* 1996; 13:93-94.
336. Poulsen LK, Bindslev-Jensen C, Diamant M, Hansen MB, Jepsen KF, Reimer CM, Bendtzen K. Biomolecular regulation of the IgE immune response. III. Cytokine profiles in atopic dermatitis, inhalent allergy and non-allergic donors. *Cytokine* 1996; 8:651-657.
337. Laham N, Brennecke SP, Bendtzen K, Rice GE. Labour-associated increase in interleukin-1a release in vitro by human gestational tissues. *J Endocrinol* 1996; 150:515-52.
338. Jakobsen PH, McKay V, N'Jie R, Olaleye BO, D'Alessandro U, Bendtzen K, Schousboe I, Greenwood BM. Soluble products of inflammatory reactions are not induced in children with asymptomatic *Plasmodium falciparum* infections. *Clin Exp Immunol* 1996; 105:69-73.
339. Bendtzen K. IIR Institute for Inflammation Research 1996; Electronic publication: <http://inet.uni2.dk/~iirrh/IIRhome.htm>.
340. Nielsen M, Svejgaard A, Skov S, Dobson P, Bendtzen K, Geisler C, Odum N. IL-2 induces b2-integrin adhesion via a Wortmannin/LY294002-sensitive, rapamycin-resistant pathway. *J Immunol* 1996; 157:5350-5358.
341. Petersen J, Bendtzen K, Halberg P, Stengaard-Pedersen K. Ciclosporin i behandlingen af reumatoid arthritis: Revideret statusrapport. Sandoz. København. 1996.
342. Homann C, Hansen MB, Graudal N, Hasselqvist P, Svenson M, Bendtzen K, Thomsen ÅC, Garred P. Anti-interleukin-6 autoantibodies in plasma are associated with an increased frequency of infections and increased mortality of patients with alcoholic cirrhosis. *Scand J Immunol* 1996; 44:623-629.
343. Buschard K, Diamant M, Bovin LF, Månsson J-E, Fredman P, Bendtzen K. Sulphatide and its precursor galactosylceramide influence the production of cytokines in human mononuclear cells. *APMIS* 1996; 104:938-944.
344. Nicoletti F, Meroni, P-L, Bendtzen K. Fusidic acid and insulin-dependent diabetes mellitus. *Autoimmunity* 1996; 24:187-197. (Review)
345. Müller K, Zak M, Nielsen S, Pedersen FK, de Nully P, Bendtzen K. In vitro cytokine production and phenotype expression by blood mononuclear cells from umbilical cords, children and adults. *Ped Allergy Immunol* 1996; 7:117-124.
346. Rasmussen ÅK, Diamant M, Blichert-Toft M, Bendtzen K, Feldt-Rasmussen U. The effects of interleukin (IL)-1b on human thyrocyte functions are counteracted by the IL-1 receptor antagonist. *Endocrinology* 1997; 138:2043-2048.
347. Rieneck K, Renneberg J, Diamant M, Gutschik E, Bendtzen K. Molecular cloning and expression of a novel *Staphylococcus aureus* antigen. *Biochim Biophys Acta* 1997; 1350:128-132.
348. Bendtzen K, Feldt-Rasmussen UF. Kemokiner og HIV-infektion. *Ugeskr Læg* 1997; 159:1956-1957. (Review)
349. Sellebjerg F, Bendtzen K, Christiansen M, Frederiksen J. Cytokines and soluble IL-4 receptors in patients with acute optic neuritis and multiple sclerosis. *Eur J Neurology* 1997; 4:59-67.
350. Abrahamsen B, Bendtzen K, Beck-Nielsen H. Cytokines and T-lymphocyte subsets in healthy post-menopausal women: Estrogen retards bone loss without affecting the release of IL-1 or IL-1ra. *Bone* 1997; 20:251-258.
351. Bygbjerg IC, Hansen MB, Ronn AM, Bendtzen K, Jakobsen PH. Decreased plasma levels of factor II+VII+X correlate with increased levels of soluble cytokine receptors in patients with malaria and meningococcal infections. *APMIS* 1997; 105:150-156.
352. Petersen J, Bendtzen K, Halberg, P., Stengaard-Pedersen K. Ciclosporin i behandlingen af reumatoid arthritis. Revideret statusrapport. København: Sandoz. Feb. 1997.

353. Jakobsen PH, Koch C, Bendtzen K. Inhibition of LPS and Plasmodium falciparum induced cytokine secretion by pentoxifylline and two analogues. *Scand J Immunol* 1997; 45:546-550.
354. Bendtzen K. Medicinsk immunologi og betændelse. *Månedsskr Prakt Lægegern* 1997; 75:569-581. (Review)
355. Laham N, Van Dunné F, Abraham LJ, Farrugia W, Bendtzen K, Brennecke SP, Rice GE. Tumor necrosis factor- α in human pregnancy and labor. *J Reprod Immunol* 1997; 33:53-69.
356. Ullum H, Victor J, Katzenstein TL, Gerstoft J, Gøtzsche PC, Bendtzen K, Skinhøj P, Pedersen BK. Decreased short-term production of tumor necrosis factor- α and interleukin-1 β in human immunodeficiency virus-seropositive subjects. *J Infect Dis* 1997; 175:1507-1510.
357. Nicoletti F, Mancuso G, Cusumano V, Di Marco R, Zaccone P, Bendtzen K, Teti G. Prevention of endotoxin-induced lethality in neonatal mice by interleukin-13. *Eur J Immunol* 1997; 27:1580-1583.
358. Asmussen K, Andersen V, Bendixen G, Bendtzen K, Prause JU, Thorn J, Wiik A, Oxholm P. Quantitative assessment of clinical disease status in primary Sjögren's syndrome. A cross-sectional study using a new classification model. *Scand J Rheumatol* 1997; 26:197-205.
359. Pedersen G, Dalseg A-M, Brynskov J, Bendtzen K. Cellaadhæsiionsmolekyleres rolle ved inflammatorisk tarmsygdom og colorektal cancer. *Ugeskr Læg* 1997; 159:5077-5084.
360. Bendtzen K. Danish Immunological Society. Electronic publ.: <http://inet.uni2.dk/~i33640/IShome.htm>.
361. Müller K, Zak M, Nielsen S, Pedersen FK, de Nully P, Bendtzen K. Interleukin-1 receptor antagonist in neonates, children and adults, and in patients with pauci- and polyarticular onset juvenile chronic arthritis. *Clin Exp Rheumatol* 1997; 15:439-444.
362. Diamant M, Rieneck K, Mechti N, Zhang XG, Svenson M, Bendtzen K, Klein B. Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin-6 signal transducer gp130. *FEBS Lett* 1997; 412:379-384.
363. Ullum H, Lepri AC, Bendtzen K, Victor J, Gøtzsche PC, Phillips AN, Skinhøj P, Pedersen BK. Low production of interferon γ is related to disease progression in HIV infection: Evidence from a cohort of 347 HIV-infected individuals. *AIDS Res Hum Retroviruses* 1997; 13:1039-1046.
364. Ross C, Svenson M, Nielsen H, Lundsgaard C, Hansen MB, Bendtzen K. Increased in vivo antibody activity against interferon α , interleukin-1 α , and interleukin-6 after high-dose Ig therapy. *Blood* 1997; 90:2376-2380.
365. Nielsen PK, Rasmussen ÅK, Butters R, Feldt-Rasmussen U, Bendtzen K, Diaz R, Brown EM, Ølgaard K. Inhibition of PTH Secretion by Interleukin-1 β in Bovine Parathyroid Glands in Vitro Is Associated with an Up-Regulation of the Calcium-Sensing Receptor mRNA. *Biochem Biophys Res Commun* 1997; 238:880-885.
366. Ciapponi L, Maione D, Scoumanne A, Costa P, Hansen MB, Svenson M, Bendtzen K, Alonzi T, Paonessa G, Cortese R, Ciliberto G, Savino R. Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist. *Nature Biotechnology* 1997; 15:997-1001.
367. Østergaard K, Petersen J, Andersen CB, Bendtzen K, Salter DM. Histologic/histochemical grading system for osteoarthritic articular cartilage: reproducibility and validity. *Arthritis Rheum* 1997; 40:1766-1771.
368. Meyer CN, Svenson M, Bendtzen K. Kemokiner og kemokinreceptorer. Nye behandlingsmuligheder ved hiv-infektion. *Tandlægebladet* 1997; 101:820-824. (Review)
369. Østergaard K, Salter DM, Andersen CB, Petersen J, Bendtzen K. CD44 expression is up-regulated in the deep zone of osteoarthritic cartilage from human femoral heads. *Histopathology* 1997; 31:451-459.
370. Bendtzen K. Immunologi. In: Lund J, Frandsen T, Löb D, Nielsen JA, Christensen M, Harding M, editors. *Den Store Danske Encyklopædi (Danmarks Nationalleksikon) - bind 9*. Kbh.: Gyldendal, 1997: pp. 274-278. (Chapter in Encyclopedia).
371. Bendtzen K. Immunterapi. In: Lund J, Frandsen T, Löb D, Nielsen JA, Christensen M, Harding M, editors. *Den Store Danske Encyklopædi (Danmarks Nationalleksikon) - bind 9*. Kbh.: Gyldendal, 1997: pp. 278-279. (Chapter in Encyclopedia).

372. Bendtzen K. Immunologiske teknikker. In: Lund J, Frandsen T, Löb D, Nielsen JA, Christensen M, Harding M, editors. Den Store Danske Encyklopædi (Danmarks Nationalleksikon) - bind 9. Kbh.: Gyldendal, 1997: p. 279. (Chapter in Encyclopedia).
373. Nicoletti F, Beltrami B, Raschi E, Di Marco R, Magro G, Grasso S, Bendtzen K, Fiorelli G, Meroni PL. Protection from concanavalin A (Con A)-induced T cell-dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate. *Clin Exp Immunol* 1997; 110:479-484.
374. Bendtzen K, Svenson M, Hansen MB. Editorial: Passive and active immunisation for specific modulation of signal peptides (cytokines). *CCC News* 1998; 1998 Nr. 1:3-5.
375. Svenson M, Hansen MB, Ross C, Diamant M, Rieneck K, Nielsen H, Bendtzen K. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. *Blood* 1998; 91:2054-61.
376. Bendtzen K, Hansen MB, Svenson M. Om Månedens Publikation: Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist. *IndenRigs* 1998; 2:6-7.
377. Rieneck K, Diamant M, Bendtzen K. DNA mikrochips: Atter en revolution indenfor bioteknologien med store kliniske og forskningsmæssige perspektiver. *Ugeskr Læg* 1998; 160:1809-10.
378. Hansen TG, Tønnesen E, Andersen JB, Toft P, Bendtzen K. The peri-operative cytokine response in infants and young children following major surgery. *Eur J Anaesthesiol* 1998; 15:56-60.
379. Rice GE, Reimert CM, Bendtzen K. Eosinophil cationic protein and eosinophil protein X: Human amniotic fluid concentrations and gestational tissue content at term. *Placenta* 1998; 19:181-85.
380. Bendtzen K, Hansen MB, Ross C, Svenson M. High-avidity autoantibodies to cytokines. *Immunol Today* 1998; 19:209-11. (Review/Hypothesis).
381. Bendtzen K. Autoantibodies to cytokines. *Eur J Clin Invest* 1998; 28: 300-1. (Review/Editorial).
382. Kemp M, Handman E, Kemp K, Ismail A, Mustafā MD, Kordofani AY, Bendtzen K, Kharazmi A, Theander TG. The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L-major. *FEMS Immunol Med Microbiol* 1998; 20:209-18.
383. Schmidt H, Bendtzen K, Mortensen PE. The inflammatory cytokine response after autotransfusion of shed mediastinal blood. *Acta Anaesthesiol Scand* 1998; 42:558-64.
384. Bendtzen K. Naturens regulation af betændelse. En kilde til forbløffelse - og praktisk udnyttelse (Månedens indlæg). *IndenRigs* 1998;16.
385. Ostergaard K, Andersen CB, Petersen J, Bendtzen K, Salter DM. Validity of histopathological grading of osteoarthritis. *Ann Rheum Dis* 1999;58:208-13.
386. Calogero AE, Nicoletti F, Palumbo MA, Burrello N, Di Mauro M, Lunetta M, Bendtzen K, Cianci A. Macrophage-derived cytokines in the follicular fluids of women with infertility due to immunological causes. Elevated levels of interleukin 6 and low levels of granulocyte macrophage-colony stimulating factor. *Cytokine* 1998;10:814-18.
387. Nielsen MB, Ødum N, Gerwien J, Svejgaard A, Bendtzen K, Bregentholt S, Röpke C, Geisler C, Dohlsten M, Kaltoft K. Staphylococcal enterotoxin-A directly stimulates signal transduction and interferon-g production in psoriatic T-cell lines. *Tissue Antigens* 1998;52:530-8.
388. Müller K, Herner EB, Stagg A, Bendtzen K, Woo P. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. *Br J Rheumatol* 1998;37:562-9.
389. Jepsen KF, Nielsen L, Olsen OT, Bendtzen K, Poulsen LK. Seasonal variations in T-lymphocyte response to grass pollen allergens from pollen-allergic patients and healthy controls. *Exp Clin Immunogenet* 1998;15:144-53.
390. Hansen TG, Tønnesen E, Toft P, Bendtzen K. Interleukin-6 (IL-6) is not removed from plasma during experimental haemofiltration. *Acta Anaesthesiol Scand* 1998;42:1129.
391. Østergaard K, Andersen CB, Houen G, Petersen J, Bendtzen K, Salter DM. Detailed description of CD44 and integrin cell adhesion molecules in normal human articular cartilage from the femoral head. *Histochem J* 1998.

392. Ostergaard K, Salter DM, Petersen J, Bendtzen K, Hvolris J, Andersen CB. Expression of a and b subunits of the integrin superfamily in articular cartilage from macroscopically normal and osteoarthritic human femoral heads. *Ann Rheum Dis* 1998;57:303-8.
393. Henriques CU, Rice GE, Wong MH, Bendtzen K. Immunolocalisation of interleukin-4 and interleukin-4 receptor in placenta and fetal membranes in association with pre-term labour and pre-eclampsia. *Gynecol Obstet Invest* 1998;46:172-7.
394. Nicoletti F, Nicoletti A, Giuffrida S, Di Marco R, Meroni P, Bendtzen K, Lunetta M. Sodium fusidate in Guillan-Barre syndrome. A case report. *J Neurol Neurosurg Psychiatry* 1998;65:266-8.
395. Wanscher M, Tønnesen E, Antonsen S, Höhndorf K, Hansen GL, Bendtzen K. Polymorphonuclear degranulation, complement activation and cytokine responses in lung cancer patients undergoing thoracic surgery. *J Cardiothor Vasc Anest* 1998;47U.
396. Strandell E, Kaas A, Hartoft-Nielsen M-L, Bock T, Buschard K, Bendtzen K. Cytokine production in NOD mice on prophylactic insulin therapy. *APMIS* 1999;107:413-9.
397. Birkeland SA, Bendtzen K, Møller B., Hamilton-Dutoit S, Andersen HK. Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. *Transplantation* 1999;27:876-81.
398. Bendtzen K, Diamant M, Rieneck K. DNA mikrochips: En revolutionerende ny teknologi i lægevidenskaben. In: *Medicus - Medicinsk Forskning 1999 (fra 2002: LexMedicus)*; electronic publ.: <http://www.sundhedsinformation.dk>.
399. Aukrust P, Ueland T, Lien E, Bendtzen K, Müller F, Andreassen AK, Nordøy I, Aass H, Espevik T, Simonsen S, Frøland SS, Gullestad L. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol* 1999;83:376-82.
400. Aukrust P, Müller F, Svenson M, Nordøy I, Bendtzen K, Frøland SS. Administration of intravenous immunoglobulin (IVIg) in vivo-down-regulatory effects on the IL-1 system. *Clin Exp Immunol* 1999;115:136-43.
401. Bendtzen K. Cellekommunikation ved betændelse. In: *Medicus - Medicinsk Forskning 1999 (fra 2002: LexMedicus)*; electronic publ.: <http://www.sundhedsinformation.dk>.
402. Bendtzen K, Meyer CN, Svenson M. HIV infektion på molekylært plan. In: *Medicus - Medicinsk Forskning 1999 (fra 2002: LexMedicus)*; electronic publ.: <http://www.sundhedsinformation.dk>.
403. Bendtzen K, Bendixen G. Den inflammatoriske reaktion. In: Lorenzen I, Bendixen G, Hansen NE, editors. *Medicinsk kompendium*. København: Nyt Nordisk Forlag Arnold Busck; 1999. pp. 129-139. (Chapter in book).
404. Bendtzen K, Bendixen G. Immunfysiologi og immunpatogenese. In: Lorenzen I, Bendixen G, Hansen NE, editors. *Medicinsk kompendium*. København: Nyt Nordisk Forlag Arnold Busck; 1999. pp. 80-110. (Chapter in book).
405. Bendtzen K, Andersen V. Immunmodulation. Terapeutiske principper. In: Lorenzen I, Bendixen G, Hansen NE, editors. *Medicinsk kompendium*. København: Nyt Nordisk Forlag Arnold Busck; 1999. pp. 63-79. (Chapter in book).
406. Østergaard K, Andersen CB, Petersen J, Bendtzen K, Salter DM. Validity of histopathological grading of articular cartilage from osteoarthritic knee joints. *Ann Rheum Dis* 1999;58:208-13.
407. Zaccane P, Phillips J, Conget I, Gomis R, Haskins K, Minty A, Bendtzen K, Cooke A, Nicoletti F. Interleukin-13 prevents autoimmune diabetes in NOD mice. *Diabetes* 1999;48:1522-8.
408. Bovin LF, Fredman P, Månsson J-E, Buschard K, Bendtzen K. In vitro production of cytokines is influenced by sulphatide and its precursor galactosylceramide. *FEBS Lett* 1999;455:339-43.
409. Bovin LF, Bendtzen K. Apoptose - programmeret celledød. *Ugeskr Læg* 1999;161:5778-82 (Review).
410. Andersen LS, Petersen J, Svenson M, Bendtzen K. Production of interleukin (IL)-1b, IL-1 receptor antagonist and IL-10 by mononuclear cells from patients with SLE. *Autoimmunity* 1999;30:235-42.
411. Bendtzen K. Tema. Nye muligheder i behandlingen af kronisk leddegigt. *Læge-Helse* 1999;12-16.
412. Bendtzen K, Rieneck K. Tema. DNA-mikrochips - den revolutionerende teknologi. *Læge-Helse* 1999;20-21.

413. Nicoletti F, Zaccone P, Conget I, Gomis R, Möller C, Meroni PL, Bendtzen K, Trepicchio W, Sandler S. Early prophylaxis with recombinant human interleukin-11 prevents spontaneous diabetes in NOD mice. *Diabetes* 1999;48:2333-9.
414. Nicoletti F, Patti F, Nicoletti A, L'Espiscopo MR, DiMarco R, Bendtzen K, Reggio A. Sodium fusidate in steroid resistant relapses of multiple sclerosis. *Mult Scler* 1999;5:377-8.
415. Nielsen H, Petersen AA, Skjødt H, Bendtzen K. Blood levels of CD11b+ memory T lymphocytes are selectively upregulated in patients with active rheumatoid arthritis. *APMIS* 1999; 107:1124-30.
416. Ødum N, Bregenholt S, Eriksen KW, Skov S, Ryder LP, Bendtzen K, Van Neerven RJ, Svejgaard A, Garred P. The CC-chemokine receptor 5 (CCR5) is a marker of, but not essential for the development of human Th1 cells. *Tissue Antigens* 1999;54:572-7.
417. Andersen LS, Petersen J, Bendtzen K. Production of interleukin (IL)-1b, IL-1 receptor antagonist and IL-10 by mononuclear cells in chronic arthritis. *Cytokine* 2000;12:62-68.
418. Meyer CN, Svenson M, Larsen CS, Ødum N, Skinhøj P, Bendtzen K. Low prevalence of antibodies and other plasma factors binding to CC chemokines and IL-2 in HIV-positive patients. *APMIS* 2000;108:122-130.
419. Bendtzen K, Rieneck K, Bovin LF. GeneChips: En revolutionerende ny teknologi. *Finsen nyt* 2000;7:8-9.
420. Bendtzen K, Marker O, Svehag S-E, Svejgaard A, Kilian M, editors. *Basal og klinisk Immunologi*. 3 ed. København: FADL's forlag A/S; 2000. 440 pages. (Book)
421. Bendtzen K, Haurum JS, Svejgaard A, Ryder LP, Ødum N, Barington T. Celleinteraktioner og regulering. In: Bendtzen K, Marker O, Svehag S-E, Svejgaard A, Kilian M, editors. *Basal og Klinisk immunologi*. 3 ed: FADL's forlag A/S; 2000. p. 67-104. (Chapter in book).
422. Bendtzen K, Poulsen LK, Wiik A, Svehag S-E. Immunpatogenese og inflammation. In: Bendtzen K, Marker O, Svehag S-E, Svejgaard A, Kilian M, editors. *Basal og Klinisk immunologi*. 3 ed: FADL's forlag A/S; 2000. p. 151-184. (Chapter in book).
423. Bendtzen K, Andersen V, Malling H-J. Immunterapi. In: Bendtzen K, Marker O, Svehag S-E, Svejgaard A, Kilian M, editors. *Basal og Klinisk immunologi*. 3 ed: FADL's forlag A/S; 2000. p. 345-359. (Chapter in book).
424. Bendtzen K. Immunologiske metoder. In: Bendtzen K, Marker O, Svehag S-E, Svejgaard A, Kilian M, editors. *Basal og Klinisk immunologi*. 3 ed: FADL's forlag A/S; 2000. p. 371-405. (Chapter in book).
425. Bendtzen K. Radial immundiffusion i gel (Mancini teknik). In: Bendtzen K, Marker O, Svehag S-E, Svejgaard A, Kilian M, editors. *Basal og Klinisk immunologi*. 3 ed: FADL's forlag A/S; 2000. p. 373-374. (Chapter in book).
426. Bendtzen K. Gelpræcipitation (Ouchterlony teknik). In: Bendtzen K, Marker O, Svehag S-E, Svejgaard A, Kilian M, editors. *Basal og Klinisk immunologi*. 3 ed: FADL's forlag A/S; 2000. p. 374-374. (Chapter in book).
427. Svehag S-E, Bendtzen K. Immunelektroforese. In: Bendtzen K, Marker O, Svehag S-E, Svejgaard A, Kilian M, editors. *Basal og Klinisk immunologi*. 3 ed: FADL's forlag A/S; 2000. p. 374-375. (Chapter in book).
428. Svehag S-E, Bendtzen K. Raket-immunelektroforese. In: Bendtzen K, Marker O, Svehag S-E, Svejgaard A, Kilian M, editors. *Basal og Klinisk immunologi*. 3 ed: FADL's forlag A/S; 2000. p. 375-6. (Chapter in book).
429. Svehag S-E, Bendtzen K. Krydset immunelektroforese. In: Bendtzen K, Marker O, Svehag S-E, Svejgaard A, Kilian M, editors. *Basal og Klinisk immunologi*. 3 ed: FADL's forlag A/S; 2000. p. 376-377. (Chapter in book).
430. Bendtzen K. Radioimmunoassay (RIA). In: Bendtzen K, Marker O, Svehag S-E, Svejgaard A, Kilian M, editors. *Basal og Klinisk immunologi*. 3 ed: FADL's forlag A/S; 2000. p. 379-379. (Chapter in book).
431. Bendtzen K. Immuno RadioMetric Assay (IRMA) og Enzyme-Linked ImmunoSorbent Assay (ELISA). In: Bendtzen K, Marker O, Svehag S-E, Svejgaard A, Kilian M, editors. *Basal og Klinisk immunologi*. 3 ed: FADL's forlag A/S; 2000. p. 380-381. (Chapter in book).
432. Koch C, Bendtzen K. Fagocyt-baktericidi. In: Bendtzen K, Marker O, Svehag S-E, Svejgaard A, Kilian M, editors. *Basal og Klinisk immunologi*. 3 ed: FADL's forlag A/S; 2000. p. 394-394. (Chapter in book).

433. Koch C, Bendtzen K. Kemotaksi: Objektglas metode. In: Bendtzen K, Marker O, Svehag S-E, Svejgaard A, Kilian M, editors. Basal og Klinisk immunologi. 3 ed: FADL's forlag A/S; 2000. p. 394-395. (Chapter in book).
434. Bendtzen K. Cytokiner: Biologisk bestemmelse af lymfocytaktiverende cytokiner. In: Bendtzen K, Marker O, Svehag S-E, Svejgaard A, Kilian M, editors. Basal og Klinisk immunologi. 3 ed: FADL's forlag A/S; 2000. p. 403-404. (Chapter in book).
435. Bendtzen K. Cytokiner: Immunometriske bestemmelser af cytokiner og opløselige cytokinreceptorer. In: Bendtzen K, Marker O, Svehag S-E, Svejgaard A, Kilian M, editors. Basal og Klinisk immunologi. 3 ed: FADL's forlag A/S; 2000. p. 404-404. (Chapter in book).
436. Stylianou E, Aukrust P, Bendtzen K, Müller F, Frøland SS. Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. *Clin Exp Immunol* 2000;119:479-485.
437. Svenson M, Hansen MB, Thomsen AR, Diamant M, Nansen A, Rieneck K, Otterness IG, Bendtzen K. Cytokine vaccination: neutralising IL-1a autoantibodies induced by immunisation with homologous IL-1a. *J Immunol Meth* 2000;236:1-8.
438. Papaccio G, Nicoletti F, Pisanti FA, Bendtzen K, Galdieri M. Prevention of spontaneous autoimmune diabetes in NOD mice by transferring in vitro antigen-pulsed syngeneic dendritic cells. *Endocrinology* 2000;141:1500-1505.
439. Saldeen J, Sandler S, Bendtzen K, Welsh N. Liposome-mediated transfer of IL-1 receptor antagonist gene to dispersed islet cells does not prevent recurrence of disease in syngeneically transplanted NOD mice. *Cytokine* 2000;12:405-408.
440. Rasmussen ÅK, Bendtzen K, Feldt-Rasmussen U. Thyrocyte-Interleukin-1 interactions. *Exp Clin Endocrinol Diabetes* 2000;108:67-71 (Review).
441. Bendtzen K, Hansen MB, Ross C, Svenson M. Detection of autoantibodies to cytokines. *Mol Biotechnol* 2000;14:251-61 (Review).
442. Jess P, Schultz K, Bendtzen K, Nielsen OH. Systemic inflammatory responses during laparoscopic and open inguinal hernia repair: A randomised prospective study. *Eur J Surg* 2000;166:540-4.
443. Pedersen G, Saermark T, Horn T, Giese B, Bendtzen K, Brynskov J. Cytokine-induced impairment of short-chain fatty acid oxidation and viability in human colonic epithelial cells. *Cytokine* 2000;12:1400-1404.
444. Myhr KM, Ross C, Nyland HI, Bendtzen K, Vedeler CA. Neutralizing antibodies to interferon (IFN) a-2a and interferon b-1a or interferon b-1b in MS are not cross-reactive. *Neurology* 2000;55:1569-1571.
445. Bendtzen K, Ross C, Hansen MB, Svenson M. Natural and induced anti-cytokine antibodies. In: Ciliberto G, Savino R, editors. *Cytokine inhibitors*. New York: Marcel Dekker; 2000. p. 53-95. (Review).
446. Ross C, Clemmesen KM, Svenson M, Sorensen PS, Koch-Henriksen N, Skovgaard GL, Bendtzen K. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. *Ann Neurol* 2000;48:706-712.
447. Nicoletti F, Di Marco R, Zaccone P, Salvaggio A, Magro G, Bendtzen K, Meroni P. Murine concanavalin A-induced hepatitis is prevented by interleukin (IL)-12 antibody and exacerbated by exogenous IL-12 through an interferon-g-dependent mechanism. *Hepatology* 2000;32:728-733.
448. Pedersen G, Saermark T, Bendtzen K, Brynskov J. Cultures of human colonic epithelial cells isolated from endoscopic biopsies from patients with inflammatory bowel disease. Effect of IFN γ , TNF α and IL-1b on viability, butyrate oxidation and IL-8 secretion. *Autoimmunity* 2000; 32:255-263.
449. Pedersen G, Saermark T, Horn T, Giese B, Bendtzen K, Brynskov J. Effects of pro-inflammatory cytokines on viability and metabolic function in human colonic epithelial cells: interplay and possible mechanisms. *Scand J Gastroenterol* 2000.
450. Sorensen PS, Ross C, Koch-Henriksen N, Svenson M, Skovgaard GL, Bendtzen K. Therapy-induced antibodies against interferon-beta-1a and interferon-beta-1b in patients with multiple sclerosis. Danish

- Multiple Sclerosis Group. In: Kappos L, Johnson K, Kesselring J, Radü EW, editors. Multiple Sclerosis. Tissue destruction and repair - New immunomodulating therapies. London: Martin Dunitz; 2000. p. 323-326.
451. Nicoletti F, Di Marco R, Conget I, Gomis R, Edwards C 3rd, Papaccio G, Bendtzen K, Sandler S. Sodium fusidate ameliorates the course of diabetes induced in mice by multiple low doses of streptozotocin. *J Autoimmunity* 2000;15:395-405.
452. Rieneck K, Bovin LF, Josefsen K, Buschard K, Svenson M, Bendtzen K. Massive parallel gene expression profiling of RINm5F pancreatic islet b-cells challenged with interleukin-1b. *APMIS* 2000;108:855-872.
453. Nicoletti F, Conget I, Di Marco R, Speciale AM, Morinigo R, Bendtzen K, Gomis R. Serum levels of the interferon-g-inducing cytokine interleukin-18 are increased in individuals at high risk of developing type 1 diabetes. *Diabetologia* 2001;44:309-11.
454. Nicoletti F, Di Marco R, Sacerdote P, Meroni P, Mangano K, Edwards C, Bartorelli A, Bendtzen K, Panerai A. Prevention and treatment of lethal murine endotoxemia by the novel immunomodulatory agent MFP-14. *Antimicrob Agents Chemother* 2001;45:1591-4.
455. Nicoletti F, di Marco R, Patti F, Reggio E, Nicoletti A, Bendtzen K, Reggio A. Increased serum levels of interleukin-18 in patients with multiple sclerosis. *Neurology* 2001;57:342-344.
456. Di Marco R, Puglisi G, Papaccio G, Nicoletti A, Patti F, Reggio A, Bendtzen K, Nicoletti F. Sodium fusidate (fusidin) ameliorates the course of monophasic experimental allergic encephalomyelitis in the Lewis rat. *Mult Scler* 2001;7:101-4.
457. Forslind K, Svensson B, Svenson M, Bendtzen K. Anti-IL-1a autoantibodies in early rheumatoid arthritis. *Scand J Rheumatol* 2001;30:167-8.
458. Bendtzen K, Bovin LF, Andersen V, Rieneck K, Svenson M. Toll-lignende receptorer. Hvad bananfluer og en musestamme kan lære os om immunsystemet. *Ugeskr Læg* 2001;163:4562-5. (Review, mini).
459. Jónasdóttir O, Petersen J, Bendtzen K. Tumour necrosis factor-a (TNF), lymphotoxin and TNF receptor levels in serum from patients with Wegener's granulomatosis. *APMIS* 2001;109:781-6.
460. Graudal N, Jürgens G, Jurik AG, Svenson M, Bendtzen K. Autoantibodies against interleukin-6 in rheumatoid arthritis. *Rheumatology* 2001;40:71-2.
461. Ross C, Engler CB, Sander B, Bendtzen K. IFN-a antibodies in patients with age-related macular degeneration treated with recombinant human IFN-a2a. *J Interferon Cytokine Res* 2002;22: 421-426.
462. Graudal N, Svenson M, Tarp U, Garred P, Jurik A-G, Bendtzen K. Autoantibodies against interleukin 1a in rheumatoid arthritis: Association with long-term radiographic outcome. *Ann Rheum Dis* 2002;61:598-602.
463. Petersen SL, Russell CA, Bendtzen K, Vindeløv LL. Optimisation of the CT.h4S bioassay for detection of human interleukin-4 secreted by mononuclear cells stimulated by phytohemagglutinin or by human leukocyte antigen-mismatched mixed lymphocyte culture. *Immunol Lett* 2002; 84: 29-39.
464. Christensen H, Boysen G, Johannesen H, Christensen E, Bendtzen K. Deteriorating ischaemic stroke: cytokines, soluble cytokine receptors, ferritin, systemic blood pressure, body temperature, blood glucose, diabetes, stroke severity, and CT infarction-volume as predictors of deteriorating ischaemic stroke. *J Neurol Sci* 2002; 201: 1-7.
465. Nicoletti F, Conget I, Di Mauro M, Di Marco R, Mazzarino MC, Bendtzen K, Messina A, Gomis R. Serum concentrations of the interferon-g-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed type 1 diabetes mellitus patients and subjects at risk of developing the disease. *Diabetologia* 2002;45:1107-10.
466. Bendtzen K, Hansen PR, Rieneck K. Novel anti-inflammatory/immunosuppressive/anti-neoplastic pharmaceutical use of Spironolactone. Rigshospitalet. Denmark, 2002 (patent).
467. Papaccio G, Nicoletti F, Pisanti FA, Galdieri M, Bendtzen K. An imidazoline compound completely counteracts interleukin-1[beta] toxic effects to rat pancreatic islet [beta] cells. *Mol Med* 2002;8:536-45.
468. Nersting J, Andersen V, Bendtzen K. Autoinflammatoriske sygdomme: et nyt begreb. *Ugeskr Laeger* 2002; 164: 4269-71.

469. Bendtzen K, Rieneck K, Hansen PR, Mazzarino MC, Di Marco R, Nicoletti F, the Spironolactone/Arthritis Study Group. Spironolactone inhibits production of proinflammatory cytokines and has potential as a new anti-inflammatory drug. *J Interferon Cytokine Res* 2002;22, Suppl.1:191-2.
470. Bendtzen K, Rieneck K, Hansen PR, the Spironolactone/Arthritis Study Group. Spironolactone inhibits production of inflammatory cytokines and has potential as a new anti-arthritic drug. In: American College of Rheumatology - 66th Annual Scientific Meeting; 2002 October 25-29, 2002; New Orleans, LA, USA; 2002.
471. Bendtzen K. Novel antiinflammatory/immunosuppressive/anti-neoplastic pharmaceutical use of a combination of Spironolactone and at least one antiinflammatory compound. Denmark. October 24, 2002 (patent).
472. Christensen H, Boysen G, Christensen E, Johannesen HH, Bendtzen K. Plasma cytokines in acute stroke. *J Stroke Cerebrovasc Dis* 2002;11:72-9.
473. Li L, Itoh M, Ablake M, Macri B, Bendtzen K, Nicoletti F. Prevention of murine experimental autoimmune orchitis by recombinant human interleukin-6. *Clin Immunol* 2002;102:135-7.
474. Svenson M, Jacobi HH, Bødtger U, Poulsen LK, Rieneck K, Bendtzen K. Vaccination for birch pollen allergy. Induction of affinity-matured or blocking IgG antibodies does not account for the reduced binding of IgE to Bet v 1. *Mol Immunol* 2003;39:603-12.
475. Bendtzen K, Bovin LF, Andersen V, Rieneck K, Svenson M. Toll-lignende receptorer. Centrale komponenter i det medfødte immunforsvar og ved overvågning af vævsskade. *Tandlægebladet* 2003;107:410-5. (Review, mini).
476. Di Marco R, Mangano K, Quattrocchi C, Musumeci R, Speciale AM, Papaccio G, Buschard K, Bendtzen K, Nicoletti F. Curative effects of sodium fusidate on the development dinitrobenzene-sulfonic acid (DNB)-induced colitis in rats. *Clin Immunol* 2003. *Clin Immunol* 2003;109:266-71.
477. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N, Danish Multiple Sclerosis Study Group. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. *Lancet* 2003;362:1184-91.
478. Nicoletti F, Di Marco R, Papaccio G, Conget I, Gomis R, Bernardini R, Sims JE, Shoenfeld Y, Bendtzen K. Essential pathogenic role of endogenous IL-18 in murine diabetes induced by multiple low doses of streptozotocin. Prevention of hyperglycemia and insulinitis by a recombinant IL-18-binding protein: Fc construct. *Eur J Immunol* 2003;33:2278-86.
479. Nersting J, Andersen V, Bendtzen K. Maturation of human dendritic cells by monocyte-conditioned medium is dependent on trace amounts of lipopolysaccharide inducing tumour necrosis factor. *Immunol Lett* 2003;89:59-65.
480. Bendtzen K, Hansen PR, Rieneck K. Spironolactone inhibits production of proinflammatory cytokines, including tumor necrosis factor a and interferon-g, and has potential in the treatment of arthritis. *Clin Exp Immunol* 2003;134:151-158.
481. Birkeland SA, Hamilton-Dutoit S, Bendtzen K. Long-term follow-up of kidney transplanted patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational tolerance, interleukin-18 course, and results of retransplantation. *Transplantation* 2003;76:153-8.
482. Kaneko T, Itoh M, Nakamura Y, Limura A, Hayashi S, Takahashi K, Stivala F, Bendtzen K, Nicoletti F. Proinflammatory effects of exogenously administered interleukin 10 in experimental autoimmune orchitis. *Cytokine* 2003;22:50-53.
483. Bendtzen K. Anti-IFN BAb and NAb antibodies - A minireview. *Neurology* 2003;61 Suppl. 5:S6-S10. (Review).
484. Bendtzen K. Immunogenicitet af biologiske lægemidler. Erfaringer med betainterferon, EPO og anti-TNF. *Ugeskr Laeger* 2003; 48:4629-32.
485. Bendtzen K. Problemer ved klinisk brug af rekombinante proteiner (leder). *Ugeskr Laeger* 2003; 48:4625.
486. BioMonitor ApS. <http://www.biomon.dk> (electronic publication - web page).
487. Pachner A, Bendtzen K, Bertolotto A, Birnbaum G, Cook SD, Cutter G, Deisenhammer F, Finter N, Freedman MS, Giovannoni G, Grossberg SE, Hartung H-P, Heine H, Johnson KP, Kappos L, Kaufman MD,

- Krementchutsky M, Munschauer F, Oger J, Petkau J, Phillips JT, Polman CH, Racke MK, Reder AT, Richert J, Richert N, Rudick RA, Schellekens H, Simsarian JP, Sorensen PS, Stark GR, Steiner I, Traboulsee A, Vartanian T, Halper J, Claudio T. Anti-IFN β antibodies in IFN β -treated MS patients. *Neurology* 2003;61, Suppl. 5:S1-S5.
488. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N. Antibodies to IFN-beta: the Danish National IFN-beta Project. *Neurology* 2003;61:S27-S8.
489. Kølsen-Petersen JA, Nielsen JO, Bendtzen K, Tønnesen E. Infusion of hypertonic saline (7.5% NaCl) causes minor immunological changes in normovolaemic women. *Acta Anaesthesiol Scand* 2004;48:224-33.
490. Bendtzen K. Natural and therapy-induced antibodies to cytokines. *Drug Discovery Today* 2004;9:259 (Editorial).
491. Gudbrandsdottir S, Larsen R, Sørensen LK, Nielsen S, Hansen MB, Svenson M, Bendtzen K, Müller K. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. *Clin Exp Rheumatol* 2004;22:118-24.
492. Sorensen PS, Ross C, Bendtzen K, Koch-Henriksen N. Neutralising antibodies against interferon beta in multiple sclerosis. *Lancet* 2004;363:168-9.
493. Bendtzen K. Den inflammatoriske reaktion. In: Hansen NE, Haunsø S, Schaffalitzky de Muckadell OB, editors. *Medicinsk kompendium*. 16 ed. København/Copenhagen: Nyt Nordisk Forlag Arnold Busck A/S; 2004. p. 59-74 (Book chapter).
494. Bendtzen K. Immunfysiologi og immunpatogenese. In: Hansen NE, Haunsø S, Schaffalitzky de Muckadell OB, editors. *Medicinsk kompendium*. 16 ed. København/Copenhagen: Nyt Nordisk Forlag Arnold Busck A/S; 2004. p. 75-101 (Book chapter).
495. Bendtzen K, Pedersen BK. Immunmodulation. In: Hansen NE, Haunsø S, Schaffalitzky de Muckadell OB, editors. *Medicinsk kompendium*. 16 ed. København/Copenhagen: Nyt Nordisk Forlag Arnold Busck A/S; 2004. p. 120-9 (Book chapter).
496. Hansen PR, Rieneck K, Bendtzen K. Spironolactone inhibits production of inflammatory cytokines by human mononuclear cells. A potential mechanism for its effect in heart failure. *Immunol Lett* 2004;91:87-91.
497. Galle P, Svenson M, Bendtzen K, Hansen MB. High levels of neutralizing IL-6 autoantibodies in 0.1% of apparently healthy blood donors. *Eur J Immunol* 2004;34:3267-3275.
498. Nielsen C, Moeller AC, Bendtzen K, Hegedüs L, Leslie GQ. Characterisation of T helper cell responses to human thyroglobulin in healthy individuals and patients with autoimmune thyroid disease. *Eur J Immunol* 2004;91:87-91.
499. Roeske-Nielsen A, Fredman P, Mansson JE, Bendtzen K, Buschard K. Beta-galactosylceramide increases and sulfatide decreases cytokine and chemokine production in whole blood cells. *Immunol Lett* 2004;91:205-11.
500. Galle P, Hougs L, Barington T, Svenson A, Svejgaard A, Thomsen AR, Bendtzen K, Hansen MB. Knocking out IL-6 by vaccination. *Eur J Immunol* 2004;34:291-300.
501. Bovin LF, Rieneck K, Workman C, Nielsen H, Sørensen SF, Skjødt H, Florescu A, Brunak S, Bendtzen K. Blood cell gene expression profiling in rheumatoid arthritis. Discriminative genes and effect of rheumatoid factor. *Immunol Lett* 2004;93:217-26.
502. Gudbrandsdottir S, Bliddal H, Petri A, Terslev L, Danneskiold-Samsøe B, Bjørnhart B, Bendtzen K, Müller K. Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis. *Scand J Rheumatol* 2004;33:385-388.
503. Sørensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Dansk Multipel Sklerose Gruppe. Betydningen af neutraliserende antistoffer mod interferon-beta hos patienter med attackvis multipel sklerose. *Ugeskr Laeger* 2004;166:3606-3609.
504. Di Paola R, Di Marco R, Mazzoni E, Genovese T, Bendtzen K, Macri M, Nicoletti F, Cuzzocrea S. Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal antibody. *Clin Immunol* 2004;113:64-73.

505. Bendtzen K. Adalimumab til behandling af aktiv reumatoid artrit. *Ugeskr Laeger* 2004; 166: 2552-2554.
506. Bendtzen K, Hansen PR, Rieneck K, The Spironolactone/Arthritis Study Group. Spironolactone hæmmer produktion af proinflammatoriske cytokiner, inklusive tumor- nekrotiserende faktor α og interferon- γ , og har terapeutisk potentiale ved reumatoid artrit. *Ugeskr Laeger* 2004;166:3203-3207.
507. Christensen H, Johannesen HH, Christensen AF, Bendtzen K, Boysen G. Serum cardiac troponin I in acute stroke is related to serum cortisol and TNF- α . *Cerebrovasc Dis* 2004;18:194-199.
508. Lindqvist E, Eberhardt K, Bendtzen K, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. *Ann Rheum Dis* 2005;64:196-201.
509. Takahashi N, Rieneck K, van der Kraan PM, van Beuningen HM, Vitters EL, Bendtzen K, van den Berg WB. Elucidation of IL-1/TGF- β interactions in mouse chondrocyte cell line by genome-wide gene expression. *Osteoarthritis Cartilage*. 2005;13:426-438.
510. Bjørnhart B, Svenningsen P, Gudbrandsdottir S, Zak M, Nielsen S, Bendtzen K, Müller K. Plasma TNF binding capacity in patients with juvenile idiopathic arthritis. *Int Immunopharmacol* 2005;5:73-77.
511. Andersen J, Heilmann C, Jacobsen N, Bendtzen K, Müller K. Cytokines and soluble TNFR1 receptor levels during pretransplant conditioning in allogeneic stem-cell transplantation. *Int Immunopharmacol* 2005;5:67-71.
512. Bendtzen K. Confirm bioavailability and rule out antibodies. 2-05 June 2005;Sect. 8.
513. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K. The Danish Multiple Sclerosis Study Group. Appearance and disappearance of neutralizing antibodies during interferon- β therapy. *Neurology* 2005;65:33-39.
514. Conget I, Aguilera E, Pellitero S, Näf S, Bendtzen K, Casamitjana R, Gomis R, Nicoletti F. Lack of effect of intermittently administered sodium fusidate to patients with newly diagnosed type 1 diabetes mellitus: the FUSIDIM trial. *Diabetologia* 2005;48:1464-1468.
515. Sellebjerg F, Ross C, Koch-Henriksen N, Sørensen PS, Frederiksen JL, Bendtzen K, Sørensen TL. CD26+CD4+ T cell counts and attack risk in interferon-treated multiple sclerosis. *Mult Scler* 2005;11:641-645.
516. Havemose-Poulsen A, Sørensen LK, Stoltze K, Bendtzen K, Holmstrup P. Cytokine profiles in peripheral blood and whole blood cell cultures associated with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid arthritis. *J Periodontol* 2005;76:2276-2285.
517. Grauballe MC, Bentzen BH, Bjornsson M, Moe D, Jonassen TE, Bendtzen K, Stoltze K, Holmstrup P. The effect of spironolactone on experimental periodontitis in rats. *J Periodontal Res* 2005;40:212-217.
518. Nielsen CH, Moeller AC, Hegedus L, Bendtzen K, Leslie RGQ. Self-reactive CD4(+) T cells and B cells in the blood in health and autoimmune disease: Increased frequency of thyroglobulin-reactive cells in Graves' disease. *J Clin Immunol* 2006; 26:126-37.
519. Andersen J, Heilmann C, Jacobsen N, Nielsen C, Bendtzen K, Müller K. Differential effect of conditioning regimes on cytokine responses during allogeneic stem cell transplantation. *Bone Marrow Transplant* 2006; 37:635-40.
520. Ross C, Svenson M, Clemmesen KM, Sørensen PS, Koch-Henriksen N, Bendtzen K. Measuring and evaluating interferon- β -induced antibodies in patients with multiple sclerosis. *Mult Scler* 2006;12:39-46.
521. Mikkelsen M, Sonder SU, Nersting J, Bendtzen K. Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression. *Apoptosis* 2006; 11:573-9.
522. Petersen B, Bendtzen K, Koch-Henriksen N, Ravnborg M, Ross C, Sorensen PS, The Danish Multiple Sclerosis Group. Persistence of neutralizing antibodies after discontinuation of IFN β therapy in patients with relapsing-remitting multiple sclerosis. *Mult Scler* 2006; 12:247-52.
523. Sonder SU, Mikkelsen M, Rieneck K, Hedegaard CJ, Bendtzen K. Effects of spironolactone on human blood mononuclear cells: mineralocorticoid receptor independent effects on gene expression and late apoptosis induction. *Br J Pharmacol* 2006; 148:46-53.

524. Havemose-Poulsen A, Wetsergaard J, Stoltze K, Skjødt H, Danneskjold-Samsøe B, Loch H, Bendtzen K, Holmstrup P. Periodontal and hematological characteristics associated with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid arthritis. *J Periodontol* 2006; 77:280-8.
525. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor Infliximab. *Arthritis Rheum* 2006; 54:3782-9.
526. Sorensen PS, Tscherning T, Mathiesen HK, Langkilde AR, Ross C, Ravnborg M, Bendtzen K. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. *Neurology* 2006; 67:1681-3.
527. El Fassi D, Nielsen CH, Bendtzen K. Rituximab (MabThera) til behandling af aktiv reumatoid arthritis. *Ugeskr Laeg* 2006; 168:4079-81.
528. Bendtzen K. Immunologi. I: Lund J, Frandsen T, Löb D, Nielsen JA, Christensen M, Harding M, eds. 9. Den Store Danske Encyklopædi (Danmarks Nationalleksikon). Kbh.: Gyldendal, 2006: 274-8.
529. Bendtzen K. Immunterapi. I: Lund J, Frandsen T, Löb D, Nielsen JA, Christensen M, Harding M, eds. 9. Den Store Danske Encyklopædi (Danmarks Nationalleksikon). Kbh.: Gyldendal, 2006: 278-9.
530. Bendtzen K. Immunologiske teknikker. I: Lund J, Frandsen T, Löb D, Nielsen JA, Christensen M, Harding M, eds. 9. Den Store Danske Encyklopædi (Danmarks Nationalleksikon). Kbh.: Gyldendal, 2006: 279-9.
531. Gottrup F, Olsen S, Bendtzen K. Betændelse. I: Lund J, Frandsen T, Löb D, Nielsen JA, Christensen M, Harding M, eds. 9. Den Store Danske Encyklopædi (Danmarks Nationalleksikon). Kbh.: Gyldendal, 2006: 561-2.
532. Zeuthen J, Bendtzen K. Cytokiner. I: Lund J, Frandsen T, Löb D, Nielsen JA, Christensen M, Harding M, eds. 9. Den Store Danske Encyklopædi (Danmarks Nationalleksikon). Kbh.: Gyldendal, 2006: 398-8.
533. Zeuthen J, Bendtzen K. Interferoner. I: Lund J, Frandsen T, Löb D, Nielsen JA, Christensen M, Harding M, eds. 9. Den Store Danske Encyklopædi (Danmarks Nationalleksikon). Kbh.: Gyldendal, 2006: 424-4.
534. Engelbrecht N, Bendtzen K. Tumornekrosefaktorer. I: Lund J, Frandsen T, Löb D, Nielsen JA, Christensen M, Harding M, eds. 9. Den Store Danske Encyklopædi (Danmarks Nationalleksikon). Kbh.: Gyldendal, 2006: 312-2.
535. Forner L, Nielsen CH, Bendtzen K, Larsen T, Holmstrup P. Increased plasma levels of IL-6 in bacteremic periodontitis patients after scaling. *J Clin Periodontol* 2006; 33:724-9.
536. Sonder SU, Woetmann A, Odum N, Bendtzen K. Spironolactone induces apoptosis and inhibits NF-kappaB independent of the mineralocorticoid receptor. *Apoptosis* 2006; 11:2159-65.
537. Nielsen CH, Albertsen L, Bendtzen K, Baslund B. Methotrexate induces PARP-dependent, caspase 3-independent apoptosis in subsets of CD4+ T cells stimulated for proliferation by conventional antigens. *Clin Exp Immunol* 2007; 148:288-295.
538. Nielsen CH, Hegedüs L, Rieneck K, Moeller AC, Leslie RGQ, Bendtzen K. Production of interleukin (IL)-5 and IL-10 accompanies T helper cell type 1 (Th1) cytokine responses to a major thyroid self-antigen, thyroglobulin, in health and autoimmune thyroid disease. *Clin Exp Immunol* 2007; 147:287-295.
539. Bovin LF, Brynskov J, Hegedüs L, Jess T, Nielsen CH, Bendtzen K. Gene expression profiling in autoimmune diseases: chronic inflammation or disease specific patterns? *Autoimmunity* 2007;40:191-201.
540. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha antistof. Individuel monitorering af biotilgængelighed og immunogenicitet – sekundærpublikation. *Ugeskr Laeg* 2007; 169:420-423.
541. Sorensen PS, Koch-Henriksen N, Bendtzen K. Are ex vivo neutralizing antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis? *Mult Scler* 2007;13:616-621.
542. Bendtzen K, Svenson M. Cytokine autoantibodies. In: Shoenfeld Y, Meroni PL, Gershwin ME, editors. *Autoantibodies*. Elsevier Press; 2007. p. 299-307.
543. El Fassi D, Nielsen CH, Bendtzen K. B-lymfocytdepletering med det biologiske lægemiddel Rituximab/MabThera® som behandling ved reumatoid artrit. *Hospital Health Care*. 2007;2:17-21.

544. Havemose-Poulsen A, Sorensen LK, Bendtzen K, Holmstrup P. Polymorphisms within the IL-1 gene cluster: Effects on cytokine profiles in peripheral blood and whole blood cell cultures of patients with aggressive periodontitis, juvenile idiopathic arthritis and rheumatoid arthritis. *J Periodontol.* 2007;78:475-492.
545. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals - assessing serum infliximab and anti-infliximab antibodies. *Rheumatology.* 2007;46:1828-1834.
546. Simard J, Bendtzen K. Diagnosis, treatment, and prevention of vascular disorders using IL-1alpha autoantibodies. 2007;Canada, Denmark (patent)
547. Galle P, Jensen L, Andersson C et al. Vaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally induced inflammation. *Int Immunopharmacol.* 2007;7:1704-1713.
548. Jorgensen KT, Wiik A, Pedersen M et al. Cytokines, autoantibodies and viral antibodies in premonitory and postdiagnostic sera from patients with rheumatoid arthritis – case-control study nested in a cohort of Norwegian blood donors. *Arthritis Rheum.* 2007;Epub ahead of print
549. Nielsen CH, El Fassi D, Hasselbalch HC, Bendtzen K, Hegedüs L. B-cell depletion with rituximab in the treatment of autoimmune diseases: Graves' ophthalmopathy the latest addition to an expanding family. *Expert Opin Biol Ther.* 2007;7:1061-1078.
550. Bendtzen K, Svenson M, Hansen MB. GM-CSF autoantibodies in pulmonary alveolar proteinosis. *New Engl J Med.* 2007;356:2001-2002.
551. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. *Am J Gastroenterol.* 2007;102:1-5.
552. Svenson M, Bendtzen K. Method for determining in vivo biopharmaceutical concentration or bioavailability. *Biomonitor A/S.* 2007;Denmark:1-51. (patent)
553. Enevold C, Bendtzen K. Prognostic method for the determination of the suitability of biopharmaceutical treatment. *Biomonitor A/S.* 2007;Denmark:1-51. (patent)
554. Sorensen LK, Havemose-Poulsen A, Sonder SU, Bendtzen K, Holmstrup P. Blood cell gene expression profiling in subjects with aggressive periodontitis and chronic arthritis. *J Periodontol* 2008;79:477-485.
555. Løbner M, Walsted A, Larsen R, Bendtzen K, Nielsen CH. Enhancement of human adaptive immune responses by administration of a high-molecular-weight polysaccharide extract from the Cyanobacterium *Arthrospira platensis*. *J Med Food* 2008;11:313-322.
556. Farrell R, Bendtzen K, Bertolotto A, Clark B, Comabella M, Deisenhammer F, Fogdell-Hahn A, Giovannoni G, Hartung HP, Hemmer B, Hillert J, Kappos L, Killestein J, Lindberg R, Montalban X, Polman C, Sorensen PS, European Study Group on interferon b-1b in secondary progressive MS. Reply: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. *J Int Med Res* 2008;36:204-208.
557. Bendtzen K, Kromminga A. Immunogenicity of interferon-beta. In: van de Weert M, Møller EH, editors. *Biotechnology: Pharmaceutical Aspects Vol. VIII. Immunogenicity of biopharmaceuticals.* Springer; 2008. p. 127-136.
558. Bendtzen K. Immunogenicity of anti-TNF antibodies. In: van de Weert M, Møller EH, editors. *Biotechnology: Pharmaceutical Aspects Vol. VIII. Immunogenicity of biopharmaceuticals.* Springer; 2008. p. 189-203.
559. Nielsen OH, Bendtzen K. Biologiske lægemidler til behandling af immuninflammatoriske sygdomme [editorial]. *Ugeskr Laeger* 2008;170:2103.
560. Bendtzen K. Immunsystemet ved kronisk inflammation. *Ugeskr Laeger* 2008;170:2110-2115.
561. Skov L, Hegedüs L, Madsbad S, Bendtzen K. Nye biologiske lægemidler til behandling af inflammatoriske sygdomme. *Ugeskr Laeger* 2008;170:2162-2163.
562. Skov L, Bendtzen K. Biologiske lægemidler til behandling af ikke-cancerrelaterede sygdomme. *Ugeskr Laeger* 2008;170:2120-2126.
563. Baslund B, Bendtzen K. Biologisk behandling af reumatoid artrit. *Ugeskr Laeger* 2008;170:2108-2110.

564. Mangano K, Sardesai N, D'Alcamo M, Libra M, Malaguarnera L, Donia M, Bendtzen K, Meroni P, Nicoletti F. In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. *Eur J Pharmacol* 2008;586:313-321.
565. Mangano K, Dati G, Quattrocchi C, Proietti L, Mazzarino C, Di Marco R, Bendtzen K, Greco B, Nicoletti F. Preventive and curative effects of cyclophosphamide in an animal models of Guillain Barré syndrome. *J Neuroimmunol* 2008;196:107-115.
566. Kolsen-Petersen JA, Bendtzen K, Tonnesen E. Infusion of hypertonic saline before elective hysterectomy: effects on cytokines and stress hormones. *Br J Anaesth* 2008;100:478-484.
567. Sorensen PS, Koch-Henriksen N, Flachs EM, Bendtzen K. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies? *Multiple Scl* 2008;14:837-842.
568. Hedegaard CJ, Krakauer M, Bendtzen H, Lund H, Sellebjerg F, Nielsen CH. T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. *Immunology* 2008;125:161-169.
569. Geismar K, Sørensen LK, Gyntelberg F, Bendtzen K, Sigurd B, Holmstrup P. Involvement of interleukin-1 genotypes in the association of coronary heart disease with periodontitis. *J Periodontol* 2008;79:2322-2330.
570. Bendtzen K. Monitorering af TNF-hæmmers biotilgængelighed, farmakokinetik og immunogenicitet muliggør bedre og billigere behandling af gigtpatienter. *BestPractice (Reumatologi)* 2008;3:8-11.
571. Atzeni F, Bendtzen K, Bobbio-Pallavicini F, Conti F, Cutolo M, Montecucco C, Sulli A, Valesini G, Sarzi-Puttini P. Infections and treatment of patients with rheumatic diseases. *Clin Exp Rheumatol* 2008;26:S67-S73.
572. Hedegaard CJ, Krakauer M, Bendtzen K, Sorensen PS, Sellebjerg F, Nielsen CH. The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis. *Clin Immunol* 2008;129:80-89.
573. Mangano K, Sardesai NY, Quattrocchi C, Mazzon E, Cuzzocrea S, Bendtzen K, Meroni PL, Kim JJ, Nicoletti F. Effects of the immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats. *Br J Pharmacol* 2008;155:722-730.
574. Hedegaard CJ, Chen N, Sellebjerg F, Sorensen PS, Leslie RG, Bendtzen K, Nielsen CH. Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: a role in regulating cytokine responses to MBP. *Immunology*. 2009;128:e451-61.
575. Radstake TRDJ, Svenson M, Eijsbouts AM, van den Hoogen FHJ, Enevold C, van Riel PLCM, Bendtzen K. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. *Ann Rheum Dis*. 2009;68:1739-1745.
576. Ravnborg M, Bendtzen K, Christensen O, Jensen PEH, Hesse D, Tovey MG, Sorensen PS. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. *Mult Scler* 2009;15:323-328.
577. Sørensen LK, Havemose-Poulsen A, Bendtzen K, Holmstrup P. Aggressive periodontitis and chronic arthritis: Blood mononuclear cell gene expression and plasma protein levels of cytokines and cytokine inhibitors. *J Periodontol* 2009;80:282-289.
578. Hesse D, Frederiksen JL, Koch-Henriksen N, Schreiber K, Stenager E, Heltberg A, Ravnborg M, Bendtzen K, Sellebjerg F, Sorensen PS. Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-beta. *Eur J Neurol* 2009;16:43-47.
579. Bendtzen K. Monitorering af TNF-alfa-hæmmers biotilgængelighed, farmakokinetik og immunogenicitet. *BestPractice (Dermatologi)* 2009;4:12-16.
580. Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. *Scand J Gastroenterol*. 2009;44:774-781.
581. Koch-Henriksen N, Sorensen P, Bendtzen K, Flachs E. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. *Mult Scler*. 2009;15:601-605.

582. Borch TS, Løbner M, Bendtzen K, Holmstrup P, Nielsen CH. Decreased interleukin-2 responses to *Fusobacterium nucleatum* and *Porphyromonas gingivalis* in generalized aggressive periodontitis. *J Periodontol.* 2009;15:601-605.
583. Enevold C, Oturai AB, Sorensen PS, Ryder LP, Koch-Henriksen N, Bendtzen K. Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1. *J Neuroimmunol.* 2009;212:125-131.
584. Larsen S, Bendtzen K, Nielsen OH. Ekstraintestinale manifestationer ved inflammatorisk tarmsygdom. *Ugeskr Laeger.* 2009;171:3078-3083.
585. Steenholdt C, Ainsworth M, Thomsen O, Brynskov J, Bendtzen K. Monitorering af tumornekrosefaktor alfa-hæmmers biotilgængelighed, farmakokinetik og immunogenicitet. *Ugeskr Laeger.* 2010;172:44-47.
586. Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management. *Ann Med.* 2010;42:97-114.
587. Enevold C, Radstake TR, Coenen MJ, Fransen J, Toonen EJ, Bendtzen K, van Riel PL. Multiplex screening of 22 single-nucleotide polymorphisms in 7 Toll-like receptors: an association study in rheumatoid arthritis. *J Rheumatol.* 2010;37:905-910.
588. Bendtzen K, Steenholdt C, Ainsworth M, Thomsen OO, Brynskov J. Predicting the response to infliximab from trough serum levels. *Gut.* 2010;59:1298-1299.
589. Borch TS, Holmstrup P, Bendtzen K, Nielsen CH. In vitro cytokine responses to periodontal pathogens: Generalized aggressive periodontitis is associated with increased IL-6 response to *Porphyromonas gingivalis*. *Scand J Immunol.* 2010;71:440-446.
590. Bendtzen K. Critical review: Assessment of interferon-beta immunogenicity in multiple sclerosis. *J Interferon Cytokine Res.* 2010;30:759-766.
591. Sena A, Bendtzen K, Cascais MJ, Pedrosa R, Ferret-Sena V, Campos E. Influence of apolipoprotein E plasma levels and tobacco smoking on induction of neutralising antibodies to interferon-beta in patients with multiple sclerosis. *J Neurol.* 2010;257:1703-1707.
592. Enevold C, Oturai AB, Sørensen PS, Ryder LP, Koch-Henriksen N, Bendtzen K. Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients. *Mult Scler.* 2010;16:942-949.
593. Damgaard S, Nielsen, CH, Andersen LW, Bendtzen K, Tvede M, Steinbrüchel DA. Cell saver for on-pump coronary surgery reduces systemic inflammatory markers: a randomized trial. *Ann Thorac Surg.* 2010;89:1511-1517.
594. Donia M, Mangano K, Quattrocchi C, Fagone P, Signorelli S, Bendtzen K, Meroni PL, Nicoletti F. Specific and strain-independent effects of dexamethasone in the prevention and treatment of experimental autoimmune encephalomyelitis in rodents. *Scand J Immunol.* 2010;72:396-407.
595. Donia M, McCubrey JA, Bendtzen K, Nicoletti F. Potential use of Rapamycin in HIV infection. *Br J Clin Pharmacol.* 2010;784-793.
596. Coenen MJH, Enevold C, Barrera P, Schijvenaars MMVAP, Toonen EJM, Scheffer H, Padyukov L, Kastbom A, Klareskog L, Barton A, Kievit W, Rood MJ, Jansen TL, Swinkels D, van Riel PLCM, Franke B, Bendtzen K, Radstake TRDJ. Genetic variants in TLR receptors are not associated with RA disease susceptibility or anti-TNF treatment outcome. *PLOS ONE.* 2010;5, e14326:1-6
597. Bendtzen K. Individualiseret behandling af gigtpatienter med biologiske lægemidler. *BestPractice (Reumatologi).* 2010;10:16-22.
598. Bendtzen K. Individualiseret behandling af dermatologiske patienter med biologiske lægemidler. *BestPractice (Dermatologi).* 2010;11:10-16.
599. Steenholdt C, Bendtzen K, Brynskov J, Thomsen O, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. *Scand J Gastroenterol.* 2010;46:310-318.
600. Lopez R, Baelum V, Hedegaard C, Bendtzen K. Serum levels of C-reactive protein in early periodontitis. *J Periodontol.* 2011;82:543-549.

601. Hedegaard CJ, Börnsen L, Bendtzen K, Sellebjerg F, Nielsen CH. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production. *Multiple Sclerosis* 2011;17:567-577.
602. Nicoletti A, Fagone P, Donzuso G, Mangano K, Dibilio V, Caponnetto S, Bendtzen K, Zappia M, Nicoletti F. Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor. *Cytokine*. 2011;55:165-167.
603. Belstrøm D, Holmstrup P, Damgaard C, Borch TS, Skjødt MO, Bendtzen K, Nielsen CH. The atherogenic bacterium *Porphyromonas gingivalis* evades circulating phagocytes by adhering to erythrocytes. *Infection and Immunity*. 2011; 79:1559-1565.
604. Lallemand C, Kavrochorianou A, Steenholdt C *et al.* Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNF α antagonists. *J Immunol Meth*. 373, 229-239 (2011).
605. Bendtzen K. Editorial: Is there a need for immunopharmacological guidance of anti-TNF therapies? *Arthritis Rheum*. 2011; 63:867-870.
606. Bendtzen K. Rationel behandling med biologiske TNF-hæmmere. *Rationel Farmakoterapi*. Juli, 1-4 (2011).
607. Vindeløv SD, Hartoft-Nielsen M-L, Rasmussen ÅK *et al.* Interleukin-8 production from human somatotroph adenoma cells is stimulated by interleukin-1 β and inhibited by growth hormone releasing hormone and somatostatin. *Growth Horm IGF Res*. 21, 134-139 (2011).
608. Steenholdt C, Svenson M, Bendtzen K, Thomsen O, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. *Aliment Pharmacol Ther*. 34, 51-58 (2011).
609. Hedegaard CJ, Enevold C, Sellebjerg F, Bendtzen K, Nielsen CH. Variation in NOD2 augments Th2- and Th17 responses to myelin basic protein in multiple sclerosis. *PLOS ONE*. 6, 1-6 (2011).
610. Nicoletti F, Fagone P, MacCubrey J, Weiner D, Bendtzen K. mTOR as multifunctional therapeutic target in HIV infection. *Drug Discov Today*. 16, 715-721 (2011).
611. Bendtzen K. Medfødt immunitet, autoimmunitet og autoinflammation. *Ugeskr Laeger*. 173, 2337-2340 (2011).
612. Bendtzen K. Danger-signaler og inflammasomer ved autoinflammatoriske og autoimmune sygdomme. *Ugeskr Laeg*. 173, 2340-2343 (2011).
613. Bendtzen K. Individualiseret behandling av dermatologiske pasienter med biologiske legemidler. *BestPractice Norge (Dermatologi)* 4,15-21 (2011).
614. Steenholdt C, Svenson M, Bendtzen K, Thomsen O, Brynskov J, Ainsworth MA. Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay. *Aliment Pharmacol Ther*. 34, 404-405 (2011).
615. Bendtzen K, Svenson M. Enzyme immunoassays and radioimmunoassays for quantification of anti-TNF biopharmaceuticals and anti-drug antibodies. In: Tovey MG, editor. *Detection and quantification of antibodies to biopharmaceuticals. Practical and applied considerations*. West Sussex, UK: A. John Wiley & Sons, Inc; 2011. p. 83-101.
616. Nielsen CH, Bendtzen K. Immunoregulation by naturally occurring and disease-associated autoantibodies: Binding to cytokines and their role in regulation of T-cell responses. *Adv. Exp. Med. Biol*. 750, 116-132 (2012).
617. Steenholdt C, Svenson M, Bendtzen K, Thomsen O, Brynskov J, Ainsworth MA. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. *J Crohns Colitis*. 6, 108-111 (2012).
618. Steenholdt C, Al-khalaf M, Brynskov J, Bendtzen K, Thomsen O, Ainsworth MA. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. *Inflamm Bowel Dis*. Feb 16. doi: 10.1002/ibd.22910. [Epub ahead of print], (2012).
619. Meyer MW, Zachariae C, Bendtzen K, Skov L. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors. *Acta Derm Venerol* 92,362-4 (2012).

620. Breindahl M, Rieneck K, Nielsen CH, Justesen T, Bendtzen K, Müller K. Cytokine responses in infants infected with respiratory syncytial virus. *Open J Immunol.* 2, 40-48 (2012).
621. Steenholdt C, Enevold C, Ainsworth MA, Brynskov J, Thomsen O, Bendtzen K. Genetic polymorphisms of tumor necrosis factor receptor superfamily 1b and Fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease. *Aliment Pharmacol Ther.* 36, 650-659 (2012).
622. Steenholdt C, Brynskov J, Bendtzen K. Persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD. *Aliment Pharmacol Ther.* 36, 499-500; author reply 501.
623. Bendtzen K. Immunfarmakologisk monitorering af patienter behandlet med biologiske TNF- α hæmmere - er det nødvendigt? *BestPractice Denmark (Reumatologi)* 2012;Nov:22-26.
624. Bendtzen K. Immunfarmakologisk monitorering av pasienter behandlet med biologiske TNF- α -hemmere - er det nødvendig? *BestPractice Norway (Reumatologi)* 2012;13:18-22.
625. Bendtzen K. Immunfarmakologisk monitorering av patienter som behandlas med biologiska TNF- α -hämmare - är det nödvändig? *BestPractice Sweden (Reumatologi)* 2012;13:24-28.
626. Bendtzen K. Immunfarmakologisk monitorering av pasienter behandlet med biologiske TNF- α -hemmere - er det nødvendig? *BestPractice Norway (Dermatologi)* 2012;13:14-18.
627. Bendtzen K. Immunfarmakologisk monitorering av patienter som behandlas med biologiska TNF- α -hämmare - är det nödvändig? *BestPractice Sweden (Dermatologi)* 2012;13:16-20.
628. Bendtzen K. Immunfarmakologisk monitorering af patienter behandlet med biologiske TNF- α hæmmere - er det nødvendigt? *BestPractice (Dermatologi)* 2012; 1-5.
629. Nielsen CH, Bendtzen K. Immunoregulation by naturally occurring and disease-associated autoantibodies : binding to cytokines and their role in regulation of T-cell responses. *Adv Exp Med Biol* (2012) 750, 116-132.
630. Bendtzen K. Anti-TNF-alpha biotherapies: perspectives for evidence-based personalized medicine. *Immunotherapy* (2012) 4, 1167-1179.
631. Steenholdt C, Bendtzen K. Antibodies against "human" biopharmaceuticals: Individualized therapy with TNF-alpha inhibitors guided by immunopharmacologic assessments. In: Schoenfeld Y, Meroni PL, editors. *Autoantibodies, 3rd Edition.* Amsterdam: Elsevier; 2013. p. 803-816.
632. Steenholdt C, Ainsworth MA, Tovey M, Klausen TW, Thomsen OO, Brynskov J, Bendtzen K. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease. *Ther Drug Monit* (2013) 35, 530-538.
633. Steenholdt C, Palarasah Y, Bendtzen K, Teisner A, Brynskov J, Teisner B, Nielsen CH. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. *Aliment Pharmacol Ther* (2013) 37, 1172-1183.
634. Nielsen CH, Steenholdt C, Palarasah Y, Bendtzen K, Teisner A, Brynskov J, Teisner B. Commentary: antibodies reacting with the infliximab Fab portion - something new? Authors' reply. *Aliment Pharmacol Ther* (2013) 38, 552-553.
635. Bendtzen K. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. *Discov Med* (2013) 15, 201-211.
636. Alamili M, Bendtzen K, Lykkesfeldt J, Rosenberg J, Gögenur I. Effect of melatonin on human night-time endotoxaemia: Randomized, double-blinded, cross-over study. *In Vivo* (2014) 28, 1057-1063.
637. Steenholdt C, Brynskov J, Thomsen OO, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. *Gut* (2014) 63, 919-927.
638. Alamili M, Bendtzen K, Lykkesfeldt J, Rosenberg J, Gögenur I. Melatonin suppresses markers of inflammation and oxidative damage in a human daytime endotoxemia model. *J Crit Care* (2014) 29, 184.e9-184.e13.

639. Enevold C, Nielsen CH, Jacobsen RS, Hermansen ML, Molbo D, Avlund K, Bendtzen K, Jacobsen S. Single nucleotide polymorphisms in genes encoding toll-like receptors 7, 8 and 9 in Danish patients with systemic lupus erythematosus. *Mol Biol Rep* (2014) 41, 5755-5763.
640. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OE, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. *Am J Gastroenterol* (2014) 109, 1055-1064.
641. Enevold C, Kjaer L, Nielsen CH, Voss A, Jacobsen RS, Hermansen ML, Redder L, Oturai AB, Jensen PE, Bendtzen K, Jacobsen S. Genetic polymorphisms of dsRNA ligating pattern recognition receptors TLR3, MDA5, and RIG-I. Association with systemic lupus erythematosus and clinical phenotypes. *Rheumatol Int* (2014) 4, 1401-1408.
642. Alamili M, Bendtzen K, Lykkesfeldt J, Rosenberg J, Gögenur I. Pronounced inflammatory response to endotoxaemia during nighttime: a randomised cross-over trial. *PLoS One* (2014) 9, e87413.
643. Steenholdt C, Bendtzen K. Immunfarmakologisk monitorering – omkostningseffektiv intervensjon hos pasienter med svikt av infliximab. *BestPractice-Gastroenterologi i Norge* (2014) 7, Mai, 20-25.
644. Steenholdt C, Bendtzen K. Immunfarmakologisk monitorering – omkostningseffektiv intervensjon hos pasienter med svikt av infliximab. *BestPractice-Revmatologi i Norge* (2014) 19, Mai, 33-37.
645. Steenholdt C, Bendtzen K. Immunfarmakologisk monitorering – omkostningseffektiv intervensjon hos pasienter med svikt av infliximab. *BestPractice-Dermatologi i Norge* (2014) 13, Mai, 2-6.
646. Steenholdt C, Bendtzen K. Immunfarmakologisk monitorering - omkostningseffektiv intervention hos patienter med svigt af infliximab. *BestPractice-Reumatologi i Danmark* (2014) August, 18-22.
647. Steenholdt C, Bendtzen K. Immunfarmakologisk monitorering - omkostningseffektiv intervention hos patienter med svigt af infliximab. *BestPractice-Dermatologi i Danmark* (2014) 13, Oktober, 15-19.
648. Halladin N, Ekelof S, Alamili M, Bendtzen K, Lykkesfeldt J, Rosenberg J, Gögenur I. Lower limb ischaemia and reperfusion injury in healthy volunteers measured by oxidative and inflammatory biomarkers. *Perfusion* (2014) DOI: 10.1177/0267659114530769.
649. Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K, Steenholdt C. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. *Inflamm Bowel Dis* (2014) 20, 1714-1721.
650. Bendtzen K, Christensen O, Nielsen CH, Holmstrup P. A matrix of cholesterol crystals, but not cholesterol alone, primes human monocytes/macrophages for excessive endotoxin-induced production of tumor necrosis factor-alpha. Role in atherosclerotic inflammation? *Discov Med* (2014) 17, 309-312.
651. Buhl SS, Steenholdt C, Brynskov J, Thomsen OO, Bendtzen K, Ainsworth MA. Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial. *BMJ Open* (2014) 4, e005887.
652. Enevold C, Geismar K, Sigurd B, Bendtzen K, Holmstrup P. Toll-like receptor 4 polymorphisms in periodontitis and coronary heart disease. *J Periodontol* (2014).
653. Mangano K, Fagone P, Bendtzen K, Meroni PL, Quattrocchi C, Mammana S, Rosa MD, Malaguarnera L, Coco M, Magro G, Marco RD, Nicoletti F. Hypomethylating agent 5-Aza-2'-deoxycytidine (DAC) ameliorates multiple sclerosis in mouse models. *J Cell Physiol* (2014) 229, 1918-1925.
654. Nielsen OH, Bendtzen K, Pedersen J. Anti-TNF-a therapy of extraintestinal manifestations of IBD. *Digestion* (2014) ???
655. Bendtzen K. Immunogenicity of anti-TNF- α biotherapies. I. Individualized medicine based on immunopharmacological evidence. *Front Immunol* (2015).
656. Bendtzen K. Immunogenicity of anti-TNF-a biotherapies: II. Clinical relevance of methods used for anti-drug antibody detection. *Front Immunol* (2015).
657. Eng GP, Bendtzen K, Bliddal H, Stoltenberg M, Szkudlarek M, Fana V, Lindegaard HM, Omerovic E, Højgaard P, Jensen E, Bouchelouche PN. Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission; a cross-sectional study. *Arthritis* (2015) doi: 10.1155/2015/784825. Epub 2015 Feb 11

658. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Munck LK, Christensen LA, Pedersen G, Kjeldsen J, Ainsworth MA. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease. *J Crohns Colitis* (2015) pii: jjv004. [Epub ahead of print]
659. Hansen JF, Bendtzen K, Boas M, Frederiksen H, Nielsen CH, Rasmussen ÅK, Feldt-Rasmussen U. Influence of phthalates on cytokine production in monocytes and macrophages: a systematic review of experimental trials. *PLOS ONE* (2015) accepted.
660. Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA. Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn's disease patients failing infliximab. *Dig Dis Sci* (2015) DOI 10.1007/s10620-015-3581-4, 1-9.
661. Nielsen, O. H., Bendtzen, K., & Pedersen, J. (2015). Anti-TNF- α therapy for extraintestinal manifestations of inflammatory bowel disease. In G. Rogler, H. Herfarth, T. Hibi, & N. OH (Eds.), *Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease* (pp. 206-213). Basel: Karger.
662. Hansen, J. F., Brorson, M. M., Boas, M., Frederiksen, H., Nielsen, C. H., Lindström, E. S. et al. (2016). Phthalates Are Metabolised by Primary Thyroid Cell Cultures but Have Limited Influence on Selected Thyroid Cell Functions In Vitro. *PLoS One*, 11(3), e0151192.
663. Steenholdt, C., Coskun, M., Buhl, S., Bendtzen, K., Ainsworth, M. A., Brynskov, J. et al. (2016). Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF- α Independent Crohn Disease. *Medicine (Baltimore)*, 95(16), e3417.
664. Steenholdt, C., Bendtzen, K., Brynskov, J., & Ainsworth, M. A. (2016). Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. *Inflamm Bowel Dis*, 22(8), 1999-2015.
665. Bendtzen, K., Steenholdt, C., Brynskov, J., Thomsen, O. Ø., & Ainsworth, M. A. (2016). Monitoring immunogenicity of protein-based TNF antagonists. *Frontline Gastroenterol*, 7(2), 152-154.
666. Eng, G. P., Bouchelouche, P., Bartels, E. M., Bliddal, H., Bendtzen, K., & Stoltenberg, M. (2016). Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study. *PLoS One*, 11(9), e0162316.
667. Steenholdt, C., Frederiksen, M. T., Bendtzen, K., Ainsworth, M. A., Thomsen, O. Ø., & Brynskov, J. (2015). Time course and clinical implications of development of antibodies against adalimumab in patients with inflammatory bowel disease. *J Clin Gastroenterol*, Jul 9. [Epub ahead of print].
668. Prado, M. S., Bendtzen, K., & Andrade, L. E. C. (2017). Biological anti-TNF drugs: Immunogenicity underlying treatment failure and adverse events. *Expert Opin Drug Metab Toxicol*, 13(9), 985-995.
669. Bendtzen, K. (2017). Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases. *UpToDate* Retrieved Oct 08, 2017, from https://www.uptodate.com/contents/tumor-necrosis-factor-alpha-inhibitors-induction-of-antibodies-autoantibodies-and-autoimmune-diseases?search=tumor-necrosis-factor-alpha-inhibitors-an-&source=search_result&selectedTitle=5~150&usage_type=default&display_rank=5.
670. Bendtzen, K., & Steenholdt, C. (2017). Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? *Aliment Pharmacol Ther*, 45(5), 759-760.
671. Maksimovic-Ivanic, D., Fagone, P., McCubrey, J., Bendtzen, K., Mijatovic, S., & Nicoletti, F. (2017). HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives. *Int J Cancer*, 140(8), 1713-1726.
672. Køllgaard, T., Enevold, C., Bendtzen, K., Hansen, P. R., Givskov, M., Holmstrup, P. et al. (2017). Cholesterol crystals enhance TLR2- and TLR4-mediated pro-inflammatory cytokine responses of monocytes to the proatherogenic oral bacterium *Porphyromonas gingivalis*. *PLoS One*, 12(2), e0172773.
673. Fagone, P., Mazzon, E., Bramanti, P., Bendtzen, K., & Nicoletti, F. (2018). Gasotransmitters and the immune system: Mode of action and novel therapeutic targets. *Eur J Pharmacol*, 834, 92-102.

674. Bendtzen, K. (2019). Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases. *UpToDate* Retrieved Oct 08, 2019, from https://www.uptodate.com/contents/tumor-necrosis-factor-alpha-inhibitors-induction-of-antibodies-autoantibodies-and-autoimmune-diseases?search=tumor-necrosis-factor-alpha-inhibitors-an-&source=search_result&selectedTitle=5~150&usage_type=default&display_rank=5.
675. Leite, F. R. M., Enevold, C., Bendtzen, K., Baelum, V., & López, R. (2018). Pattern recognition receptor polymorphisms in early periodontitis. *J Periodontol*, *90*, 647-654.
676. Bendtzen, K., Prado, M. S., & Andrade, A. A. (2018). Behandling af kronisk inflammatoriske sygdomme med anti-TNF biofarmaka. *Tandlægebladet*, *122*, 846-853.
677. Enevold, C., Nielsen, C. H., Molbo, D., Lund, R., Bendtzen, K., Fiehn, N. et al. (2019). Lewis and AB0 blood group-phenotypes in periodontitis, cardiovascular disease, obesity and stroke. *Sci Rep*, *9*(1), 6283.
678. Petralia, M. C., Mazzon, E., Fagone, P., Basile, M. S., Lenzo, V., Quattropiani, M. C. et al. (2020). Pathogenic contribution of the Macrophage migration inhibitory factor family to major depressive disorder and emerging tailored therapeutic approaches. *J Affect Disord*, *263*, 15-24.
679. Petralia, M. C., Mazzon, E., Fagone, P., Basile, M. S., Lenzo, V., Quattropiani, M. C. et al. (2020). The cytokine network in the pathogenesis of major depressive disorder. Close to translation. *Autoimmun Rev*, *19*(5), 102504.
680. Bodio, C., Grossi, C., Pregnotato, F., Favalli, E. G., Biggioggero, M., Marchesoni, A. et al. (2020). Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. *Autoimmun Rev*, *19*(5), 102509.
681. Russo A, Bendtzen K, Nicoletti F. Covid-19: nuovo approccio farmacologico evidenziato da ricerca internazionale. 2020;
682. Fagone P, Ciurleo R, Lombardo SD et al. Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies. *Autoimmun Rev* 2020; 102571.
683. Buhl S, Dorn-Rasmussen M, Brynskov J et al. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease. *Scand J Gastroenterol* 2020; 55:884.
684. Bendtzen K. Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases. *UpToDate* 2021;
685. Bendtzen K. Are microbiomes involved in paroxysmal atrial fibrillation?? Repeated clinical improvement after pivmecillinam (amdinocillin) therapy. *Academia Letters* 2021; Article 3124:DOI 10.20935/AL3124.
686. Buhl S, Steenholdt C, Brynskov J et al. Discontinuation of infliximab therapy in patients with Crohn's disease in combined clinical-biochemical-endoscopic remission: A double-blinded, placebo-controlled, randomized clinical trial. *NEJM Evidence* 2022;
687. Steenholdt C, Thomsen OO, Brynskov J et al. Discriminating between response types in infliximab-treated patients with Crohn's disease: Sensitivity and specificity of combined assessment of infliximab trough levels and anti-drug antibodies. *AGA* 2022; W1270:S687.
688. Bendtzen et al. Interleukin-6 and Tumour Necrosis Factor Alpha Synthesized by Cholesteatoma Cells Affect Mucociliary Function in the Eustachian Tube.
- 689.